42nd Annual Congress of the

Canadian Neurological Sciences Federation

42ème congrès annuel de la

Fédération des sciences neurologiques du Canada

Final Program / Programme final
New age. Healthy age.

As a leading research-based pharmaceutical company, we're committed to making every age a healthy age. Because we believe in great beginnings, too.

Working for a healthier world™

www.pfizer.ca
Scientific Program Chair, John Stewart, Vice Chair Mike Tymianski, their Committee members, the CNSF Board, staff and I welcome you to the 42nd Congress of the Canadian Neurological Sciences Federation.

We hope you will enjoy the Program this year. It won’t take you long to discover some of the exciting changes we’ve made to the Congress in our continuing effort to provide our delegates the most comprehensive meeting of neurologists, neurosurgeons and neuroscientists in the country.

Some features new to the Congress this year that you should take note of are:

1. A Distinguished Guest Lecture. We are pleased to announce that Michael Bliss will be speaking on “From Osler to Cushing-The Rise of Medicine, The Rise of Neurosurgery” in the first of what we are sure will be a highly anticipated Congress feature in the years to come.
2. Digital Posters on display in the exhibit area. Fully navigable and categorized according to station, we are sure this departure from physical posters will give greater value to interested delegates and authors.
3. A smaller more intimate exhibit area featuring most of this year’s sponsors, whose support makes this Congress possible. Please visit the exhibit area! It is important to do so.

During this Congress there will be opportunities for you to:

1. Network with colleagues, mentors and friends.
2. Rejuvenate your practice with additional knowledge and skill.
3. Stimulate your thinking.
4. Earn Section 1 MOC Credits.
5. Work on your personal learning needs.

We hope you find this Congress as educational, broad based, innovative, creative and exciting as we do.

Please make sure you tell us how we are doing by completing the Session Specific Evaluation Forms, which will be in the Course and other session rooms, and the Overall Congress Evaluation available on line and in your registration portfolio. It is important that you provide us this feedback so we can continue to improve and better meet your learning needs.

Again, welcome and Thank you.

Yours truly,

Mark Hamilton
President
CNSF

John Stewart
Chair
Scientific Program Committee

CNSF Executive Committee
Mark Hamilton, CNSF Chair
Garth Bray, CNSF Vice-President
Brian Wheelock, CNSF Vice-President
Dan Morin, CNSF Chief Executive Officer (ex-officio)

Scientific Program Committee
John Stewart, Chair CNS
Mike Tymianski, Vice-Chair
Jeanne Teitelbaum, CNS
Michael Hill, CNS
Christopher Honey, CNSS
Eric Massicotte, CNSS
Joseph Chu, CSCN
Seyed Mirsattari, CSCN
Juliette Hukin, CACN
Elaine Wirrell, CACN
Susan Brien, Chair, Professional Development Committee

Congress Organizers
Advance Group, Conference Management
Suite 101-1444 Alberni Street
Vancouver, BC V6G 2Z4
Tel: 1-800-555-1099 (ext 2) Fax: (604) 685-3521
E-mail: cnsf2007@advance-group.com
Contact: Jo-ann Roy, Conference Manager

Canadian Neurological Sciences Federation
709 – 7015 Macleod Trail SW
Calgary, AB,
Canada T2H 2K6
Tel: (403) 229-9544
Fax: (403) 229-1661
E-mail: brett-windle@cnsfederation.org
A leader in hemostasis research and proud sponsor of the Canadian Neurological Sciences Federation 42nd Annual Congress

Partners in the Management of Acute Stroke Care
# TABLE OF CONTENTS / TABLE DES MATIÈRES

Daily Events Calendar ................................................................. 4
  Scientific Sessions
  Business Meetings
  Social Events
Daily Scientific Sessions ............................................................. 6
  Meetings at a Glance
Exhibition Hall ............................................................................... 7
General Meeting Information ......................................................... 8
Maintenance of Certification .......................................................... 10
  How to obtain CME credits
Plenary Guest Speakers ................................................................. 11
Detailed Scientific Program
  Tuesday, June 19, 2007 ............................................................... 17
  Wednesday, June 20, 2007 .......................................................... 21
  Thursday, June 21, 2007 ............................................................. 25
  Friday, June 22, 2007 ................................................................. 26
Winners of the 2007 Society Prizes ................................................ 32
Platform Presentations ................................................................. 33
Poster Presentations ..................................................................... 40
2007 Exhibitors ............................................................................. 46

Accreditation FRCPC ou FRCSC ................................................... 10
  Comment obtenir des crédits CME
Reseignements D’ordre Général .................................................... 50
  Programme scientifique
  Réunion d’affaires
  Activités sociales
Programme des Activités ............................................................ 52
Programme Scientifique
  Mardi 19 juin 2007 ................................................................. 54
  Mercredi 20 juin 2007 ............................................................... 58
  Jeudi 21 juin 2007 ................................................................. 62
  Vendredi 22 juin 2007 .............................................................. 63
## Monday, June 18, 2007

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-16:30</td>
<td>CNSF/CJNS Board &amp; Planning Meetings</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>CJNS Audit Committee</td>
<td>Boardroom Fairmont</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>CNSF Audit Committee</td>
<td>Boardroom Fairmont</td>
</tr>
<tr>
<td>16:30-17:30</td>
<td>CACN Council Meeting</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>15:00-17:00</td>
<td>Speaker Preparation Room</td>
<td>Salon 7</td>
</tr>
</tbody>
</table>

## Tuesday, June 19, 2007

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-18:30</td>
<td>Registration</td>
<td>Meeting Level Foyer</td>
</tr>
<tr>
<td>07:00-18:00</td>
<td>Speaker Preparation Room</td>
<td>Salon 7</td>
</tr>
<tr>
<td>07:30-08:30</td>
<td>CNS Alberta Chapter AGM</td>
<td>Salon 1</td>
</tr>
<tr>
<td>08:00-17:00</td>
<td>Neurobiology Review Course</td>
<td>Salon 4</td>
</tr>
<tr>
<td>08:30-17:00</td>
<td>ALS Strategies for Quality Life/Quality Care Symposium Course</td>
<td>Salon 3</td>
</tr>
<tr>
<td>08:30-17:00</td>
<td>Child Neurology Day</td>
<td>Salon 2</td>
</tr>
<tr>
<td>09:00-11:00</td>
<td>CNSF Professional Development Committee</td>
<td>Salon 5/6</td>
</tr>
<tr>
<td>10:00-12:00</td>
<td>CNSF Scientific Program Committee</td>
<td>Salon 5/6</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>ALS Lunch</td>
<td>Salon 12</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Neurology Residents CNS Meeting</td>
<td>Wedgewood Fairmont</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>C SCN EMG Committee</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>C SCN EEG Committee</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>12:30-16:30</td>
<td>CNS Education &amp; Manpower, RC Specialty Committee Neurology</td>
<td>Salon 1</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>CJNS Editorial Board</td>
<td>Salon 19/20</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>CJNS Publications Committee</td>
<td>Salon 19/20</td>
</tr>
<tr>
<td>13:00-15:30</td>
<td>ALS Breakout 2</td>
<td>Salon 15/16</td>
</tr>
<tr>
<td>13:00-15:30</td>
<td>ALS Breakout 3</td>
<td>Salon 13/14</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>C SCN Council Meeting</td>
<td>Salon 1</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>CNSS Council Meeting</td>
<td>Salon 20</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>CNS Council Meeting</td>
<td>Salon 19</td>
</tr>
<tr>
<td>16:30-17:30</td>
<td>Neurosurgery Residents Business Meeting</td>
<td>Salon 17</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>CACN Annual General Meeting</td>
<td>Salon 15/16</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Epilepsy Video Session (Course)</td>
<td>Salon 4</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Movement Disorders</td>
<td>Wedgewood Fairmont</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>ALS SIG</td>
<td>Jasper Room Fairmont</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Neuromuscular SIG</td>
<td>Salon 3</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Neurosurgery Residents Education Meeting SIG</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Undergraduate Neurological Education</td>
<td>Salon 13 &amp; 14</td>
</tr>
<tr>
<td>18:30</td>
<td>CACN Dinner - Ruth’s Chris Steak House</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>07:00-08:30</td>
<td>Registration</td>
<td>Meeting Level Foyer</td>
</tr>
<tr>
<td>08:30-09:30</td>
<td>Annual General Meeting (AGM)</td>
<td>Salon 10</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>CBANHC Report</td>
<td>Salon 12</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Reviewer of the Year Award Presentation &amp; Introduction of new CJNS Editor</td>
<td>Salon 12</td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>Poster &amp; Exhibit Viewing</td>
<td>Salons 8, 9, 10 &amp; 11</td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>CBANHC Meeting</td>
<td>Salon 17 &amp; 18</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Lunch in Exhibit Hall &amp; Poster Tours</td>
<td>Salons 8, 9, 10 &amp; 11</td>
</tr>
<tr>
<td>12:30-14:00</td>
<td>Lunch in Exhibit Hall &amp; Poster Viewing</td>
<td>Salons 8, 9, 10 &amp; 11</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Headache Course</td>
<td>Drawing Room</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>What's New In Neurosurgery Course</td>
<td>Fairmont</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>EEG Course</td>
<td>Salon 4</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Dementia Course</td>
<td>Salon 3</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>MS Course</td>
<td>Salons 5/6</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>What's New in Neurology Course</td>
<td>Wedgewood</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Neur muscular Course</td>
<td>Fairmont</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>CNSF/CNS Board Meeting</td>
<td>Salon 12</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Canadian Headache Outpatient &amp; Data Base Group Meeting</td>
<td>Salon 17 &amp; 18</td>
</tr>
<tr>
<td>17:00-22:00</td>
<td>CANN Fun Run/Walk for Neuroscience Nursing</td>
<td>Salons 8, 9, 10 &amp; 11</td>
</tr>
</tbody>
</table>

**Abbreviation Guide**

- Annual General Meeting (AGM)
- Canadian Association of Child Neurology (CACN)
- Canadian Neurological Sciences Federation (CNSF)
- Canadian Journal of Neurological Sciences (CJNS)
- Canadian Neurological Society (CNS)
- Canadian Neurosurgical Society (CNSS)
- Canadian Society of Clinical Neurophysiologists (CSCN)
- Special Interest Groups (SIGs)

Blue type shows scientific program events;
Black shows business and other meetings.
### SCIENTIFIC SESSIONS – MEETING AT A GLANCE

#### TUESDAY
June 19, 2007

- **08:00-17:00**  Neurobiology Review Course  
  page 17
- **08:30-17:00**  ALS Strategies for Quality Life/Quality Care  
  page 18
- **08:30-17:00**  Child Neurology Day - Controversies and Advances in Neonatal Neurology  
  page 19
- **18:00-20:00**  Epilepsy Video Session  
  page 20
- **18:00-20:00**  Movement Disorders Management - Drugs to Surgery  
  page 20
- **18:00-20:00**  SPECIAL INTEREST GROUPS  
  ALS, Neuromuscular, Neurosurgery Residents’ Education, Undergraduate Neurological Education  
  page 20

#### WEDNESDAY
June 20, 2007

- **08:30-10:30**  Grand Opening Plenary: Scientific and Technical Advances in the Clinical Neurosciences  
  page 21
- **10:45-12:15**  Chair’s Select Plenary Presentation  
  page 21
- **14:00-17:30**  Neuropathic Pain: Pathophysiology, Prevention and Management  
  page 21
- **14:00-17:30**  Spine Course - The Triage and Management of the Cervical Spondylotic Myelopathy Patient  
  page 22
- **14:00-17:30**  Clinical Electromyography Course  
  page 23
- **14:00-17:30**  Stroke Course  
  page 23
- **14:00-17:30**  Epilepsy Course: Intractable Epilepsy  
  page 24
- **14:00-17:30**  Neurocritical Care Course  
  page 24

#### THURSDAY
June 21, 2007

- **08:30-10:00**  Plenary Session: CNS, CACN and CSCN Neurology  
  page 25
- **10:15-12:30**  Platform Sessions (6 concurrent)  
  page 25
- **12:30-14:00**  Digital Poster and Exhibit Viewing  
  page 25

#### FRIDAY
June 22, 2007

- **08:30-09:30**  Distinguished Guest Lecturer  
  page 26
- **09:30-09:50**  The CBANHC Report  
  page 26
- **09:50-10:15**  Digital Poster and Exhibit Viewing  
  page 26
- **10:15-12:00**  Grand Rounds  
  page 26
- **12:00-13:30**  Digital Poster and Exhibit Viewing  
  page 26
- **13:30-17:00**  Headache Course  
  page 27
- **13:30-17:00**  What’s New in Neurosurgery?  
  page 27
- **13:30-17:00**  EEG Course  
  page 28
- **13:30-17:00**  Dementia Course  
  page 28
- **13:30-17:00**  MS Course  
  page 29
- **13:30-17:00**  What’s New in Neurology?  
  page 30
- **13:30-17:00**  Neuromuscular Course  
  page 31
Booth Assignments

EEXHIBITION HALL

Bayer Healthcare .................. .1
Biogen Idec Canada .................. .20
Boehringer Ingelheim .................. .31
Bristol Myers Squibb / sanofi-aventis ........ .8
Canada Microsurgical Ltd .................. .12
Carl Zeiss Canada .................. .24
Codman/Johnson & Johnson .................. .3
Galen Medical Ltd. .................. .27
Janssen-Ortho Inc .................. .16
Leica Microsystems .................. .11
Medtronic of Canada Ltd .................. .37
Merck Frosst Canada Ltd .................. .22
Novartis .................. .6
Novo Nordisk Canada Inc .................. .26
Pfizer Canada .................. .14
Prestwick Pharmaceuticals Canada .................. .25
Hoffman LaRoche .................. .19
Roxon Medi-Tech Ltd .................. .36
Talecris Biotherapeutics .................. .18
Teva Neuroscience .................. .30
Valeant Canada Ltd .................. .13
XLTEK .................. .10

Due to space constraints, the following requested but were not provided exhibiting opportunities:

- Grass Technologies
- Karl Storz Endoscopy Canada
- Kyphon Inc.
- Stellate
- Stryker Canada
- Summit Technologies

A new feature of the Congress; we are presenting posters digitally this year. Please take note of the station locations on the Exhibition Hall floorplan. Each station contains abstracts organized by category for easy reference. Please take a moment to visit these stations and tour the Exhibit Hall.
GENERAL MEETING INFORMATION

MEETING LOCATION AND REGISTRATION

Meeting Site
Shaw Conference Centre
9797 Jasper Avenue
Edmonton, Alberta Y5J 1N4

Delegate & Exhibitor Registration – On Site
Registration Desk
Shaw Conference Centre

Tuesday, June 19
07:30 – 18:30

Wednesday, June 20
07:00 – 18:30

Thursday, June 21
07:00 – 18:30

Friday, June 22
07:00 – 13:30

Registration Details

Full Registration
• Full registrants can attend all sessions of the 2007 Annual Congress from Tuesday, June 19 through Friday, June 22.
• Includes the Exhibitors’ Reception and the Presidents’ Reception on Wednesday, June 20 and the Presidents’ Dinner on Thursday June 21, plus lunch in the Exhibit Hall on Thursday and Friday.

One-Day Registration
• One-day registrants can attend scientific sessions only, on one of Tuesday, Wednesday, Thursday or Friday.
• Does not include the Presidents’ Reception, or the Presidents’ Dinner, but tickets are available for purchase for these events.

Badges
• Delegates must wear their badges at all times to gain entry to Congress Courses, Scientific Sessions and evening events. Tickets will be collected for the Presidents’ Reception and the Presidents’ Dinner for those who have purchased extra tickets.

Registration Forms
• You can register online at www.cnsfederation.org., or the forms can be also mailed or faxed to:

Advance Group Conference Management
Suite 101 - 1444 Alberni Street
Vancouver, BC, Canada V6G 2Z4
Fax: +1-604-685-3521

Future Meetings of the Canadian Neurological Sciences Federation

June 17 – 20, 2008 Victoria, British Columbia
June 9 – 12, 2009 Halifax, Nova Scotia
June 8 – 11, 2010 Quebec City, Quebec

Questions?
Advance Group
Attention: Canadian Neurological Sciences Federation
Suite 101 - 1444 Alberni Street
Vancouver, BC, Canada V6G 2Z4
Phone: +1-604-688-9655 (Extension 2)
1-800-555-1099 (Extension 2)
Fax: +1-604-685-3521
E-mail: cnsfinfo@advance-group.com

edmonton
alberta
ACCOMMODATION INFORMATION

Support your Federation by booking your hotel stay with a CNSF partner hotel and receive a reduced rate! The Advance Group has been assigned as the Official Housing Bureau for the 42nd Congress of the Canadian Neurological Sciences Federation to be held in Edmonton, Alberta, June 19 - 22nd, 2007. Please be sure to take advantage of the special hotel rates available only to the Congress delegates.

Preferential Rates

The CNSF has a block of rooms reserved and has established preferential rates for conference delegates at the following hotels:

Fairmont MacDonald
- Single or Double $199
- View Room $219
- Deluxe Room $239
- Deluxe View $259
3rd and 4th person add $20.00/person/night to room type above.

Westin
- Single or Double $165
3rd and 4th person add $25.00/person/night to room type above.

Booking Hotels

- Reservations process: The Advance Group accepts hotel requests online at www.cnsfederation.org or in writing via fax (604-685-3521) or mail using the CNSF Hotel Reservation Form. Reservations will not be accepted by telephone.
- Hotel enquiries, questions or any group request of 10 rooms or more, can be sent to the following email address: cnsf2007@advance-group.com.
- Hotel reservations will be assigned on the information received and on a first come, first served basis, based on the hotel and room availability.
- Individual Reservations: Each room requested does require a one night deposit to confirm, payable either by credit card or cheque/money order made payable to the Advance Group. This cheque or money order (CANADIAN FUNDS) must accompany the hotel form in order for your reservation to be processed. Please submit one form for each room reservation.
- Hotel confirmations are forwarded directly to you via email, fax or mail.
- Hotel Cancellation: Cancellations made within 48 hours prior to arrival will be charged a one-night penalty by the hotel.
- All hotel prices are quoted in Canadian dollars, per room, per night. Rates are subject to an additional 4% hotel tax, 6% GST and 1% Tourism Levy. Visitors residing outside of Canada are eligible for a GST rebate on the guest room portion of their bill. GST rebate forms are available for you at your hotel when checking out.

SOCIAL EVENTS

Exhibitors’ Reception
Wednesday, June 20, 2007 - 17:30-19:00
Shaw Conference Centre - Meeting level-exhibit area
Wine & Cheese. Cash bar. Must have badges for entry.

Presidents’ Reception
Wednesday, June 20, 2007 - 19:00-21:00
Empire Ballroom, Fairmont MacDonald
Business attire. Refreshments and hors d’oeuvres. 2 complimentary drink tickets, then cash bar. Part of package for full registrants, tickets will be issued and collected at door. Extra tickets are also available for purchase at $30 each (plus tax).

Residents’ Soirée
Thursday, June 21, 2007 - 18:00-19:00
Shaw Conference Centre Salon 5/6
All residents are invited to meet and mingle with their colleagues and CNSF board members. Includes complimentary beverages.

Presidents’ Dinner
Thursday, June 21, 2007 - 19:00
Shaw Conference Centre - Hall D on the Pedway Level
Business attire. Four course dinner, entertainment. This dinner is part of the full conference registration. Your badge will be required to enter. For those who purchased extra tickets, they will be collected at the door. Extra tickets are available for purchase at $75 each (plus tax).
M A I N T E N A N C E O F C E R T I F I C A T I O N / M A I N T I E N D U C E R T I F I C A T

The 42nd Annual Congress of the Canadian Neurological Sciences Federation is an accredited learning activity approved by the CNS and the CNSS, as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The Royal College of Physicians and Surgeons of Canada established the Maintenance of Certification program on January 1, 2001. Participation in this program is a requirement for admission to and renewal of Fellowship and for the use of the designations FRCPC and FRCSC.

The 2007 Congress has been approved for Section 1 under the Maintenance of Certification program. This means each attendee is assigned one credit per hour in education sessions. Breaks, lunch, and the poster sessions are excluded.

As Fellows are responsible for keeping track of their hours of participation in educational activities, they should keep a copy of this meeting program and their registration form for future reference. Certificate of Attendance Forms will only be issued once you have completed the Overall Congress Evaluation on line through a link we will be providing to all delegates, or completed the hard copy we will have in the delegates portfolio distributed at the Congress and faxed it to the CNS Secretariat at 1-403-229-1661. The deadline for completion and submission is June 30th, 2007.

For more information about the Maintenance of Certification Program, please refer to the Royal College website http://www.rcpsc.medical.org or e-mail the CNS secretariat office at info@cnsfederation.org

CME HOURS  Breaks, lunch and poster sessions are excluded

<table>
<thead>
<tr>
<th>Date: Tuesday, June 19, 2007</th>
<th>Date: Thursday, June 21, 2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurobiology Review Course</td>
<td>Plenary Session: CNS, CACN and C SCN Neurology</td>
</tr>
<tr>
<td>ALS Strategies for Quality of Life/Quality Care</td>
<td>Plenary Session: CNSS Neurosurgery</td>
</tr>
<tr>
<td>Child Neurology Day-Controversies and Advances in Neonatal Neurology</td>
<td>Platform Sessions - Morning</td>
</tr>
<tr>
<td>Epilepsy Video Session</td>
<td>Platform Sessions - Afternoon</td>
</tr>
<tr>
<td>Movement Disorders Management: Drugs to Surgery</td>
<td>Date: Friday, June 22, 2007</td>
</tr>
<tr>
<td>2.0</td>
<td>Distinguished Guest Lecturer</td>
</tr>
<tr>
<td>2.0</td>
<td>Grand Rounds</td>
</tr>
<tr>
<td>2.0</td>
<td>Headache Course</td>
</tr>
<tr>
<td>2.0</td>
<td>What’s New in Neurosurgery Course</td>
</tr>
<tr>
<td>3.0</td>
<td>EGG Course</td>
</tr>
<tr>
<td>1.5</td>
<td>Dementia Course</td>
</tr>
<tr>
<td>3.5</td>
<td>MS Course</td>
</tr>
<tr>
<td>3.0</td>
<td>What's New in Neurology</td>
</tr>
<tr>
<td>3.5</td>
<td>Neuromuscular Course</td>
</tr>
<tr>
<td>3.5</td>
<td>Total CME Hours</td>
</tr>
<tr>
<td>3.5</td>
<td>81.0</td>
</tr>
<tr>
<td>3.0</td>
<td>81.0</td>
</tr>
</tbody>
</table>
Anthony A. Amato

Anthony A. Amato, M.D. graduated Magna Cum Laude with a B.S. degree at Case Western Reserve University in 1982 and had a fully paid scholarship (US Air Force) for medical school at the University of Cincinnati where he obtained his M.D. degree in 1986. He did his internal medicine internship and neurology residency at Wilford Hall Medical Center (WHMC) in San Antonio and his neuromuscular fellowship Ohio State University with Jerry Mendell, M.D. Dr. Amato returned to WHMC as the Chief of the Neuromuscular Division from 1992-1996. After fulfilling his military obligation, he joined the Department of Neurology at the University of Texas Health Science Center at San Antonio where he was co-chairman of the Neuromuscular Service.

In August 1999 following a national search, he was recruited to Brigham and Women’s Hospital (BWH) to be the Chief of the Neuromuscular Division and Director of the Clinical Neurophysiology Laboratory with an appointment as Associate Professor of Neurology at Harvard Medical School. He is now the vice-chairman of the Department of Neurology at BWH. He initiated and directed the integrated BWH-MGH Clinical Neurophysiology Fellowship program which is ACGME. In 2006, he started an ACGME-approved Neuromuscular Medicine Fellowship (6 new fellows per year) that encompasses BWH, MGH and Children’s Hospital.

Dr. Amato has been a principle investigator or co-investigator in many clinical trials sponsored by the NIH, FDA, or industry in various neuromuscular disorders. He is a founding member of the Muscle Study Group, a consortium of scientific investigators from academic and research centers who are committed to the cooperative planning, implementation, analysis and reporting of controlled clinical trials and of other research for muscle and other neuromuscular diseases. The MSG aims to advance knowledge about causes, pathogenesis, epidemiology, and clinical manifestations of muscle disease and related neuromuscular disorders and to develop and implement strategies to examine promising therapeutic interventions.

Dr. Amato is a grant reviewer for the NIH and The Myositis Association. He is a member of the Data and Safety Monitoring Board (DSMB) for all gene therapy trials for the National Heart, Lung and Blood Institute and also a member of the DSMB for the Familial Amyloid Polyneuropathy Trial for NINDS/NIH. He is Associate Editor for Muscle & Nerve. He has authored or co-authored 91 journal articles, 45 book chapters, and 2 books.

Amin B. Kassam

Amin Kassam, MD, completed his medical and undergraduate education at the University of Toronto and his residency and fellowship training at the University of Ottawa. Dr. Kassam pursued additional post-graduate training in epidemiology and clinical outcomes. Dr. Kassam joined the faculty of the Department of Neurological Surgery at the University of Pittsburgh in February of 1998. He spent the next year focusing on microvascular surgery. Dr. Kassam has performed over 1,000 microvascular decompression procedures for cranial nerve neuropathy and has provided a unique perspective by using the endoscope to visualize and enhance difficult regions. Since his appointment, he has also focused on building a collaborative center to provide comprehensive care for complex pathology of the skull base. This center builds on the strength of combining the talents of surgeons from multiple specialties. This allows for the use of proven conventional approaches in conjunction with new minimally invasive endoscopic approaches to provide safe and effective treatment for patients. This has culminated in the development of the multidisciplinary Minimally Invasive Neurosurgical Center (MINC). Dr. Kassam along with Carl Snyderman, MD, and Ricardo Carrau, MD, were directly involved with the development of the Expanded Endonasal Approach (EEA). This approach represents an entirely new paradigm to remove complex lesions of the skull base and brain without incisions. The center, under the direction of Dr. Kassam, has pioneered and developed much of the technology and instrumentation used during the EEA surgeries. With continued research and experience, he now uses the EEA surgery for most tumors affecting the skull base. Dr. Kassam has performed over 3,000 neurosurgical procedures including over 700 minimally invasive endoscopic procedures. Dr. Kassam remains active in cerebrovascular surgery and has helped to develop a program to better understand the genetic alterations that lead to the development of intracranial aneurysms.

In July 2006, Dr. Kassam was named Interim Chairman of the Department of Neurological Surgery. Since then he has focused on increasing interdisciplinary activities between neurosurgery and radiology, medical, radiation and surgical oncology, anesthesiology, neurology, and otorhinolaryngology. It is hoped that these cooperative ventures will lead to new innovations in care for patients with a variety of neurologic abnormalities. Dr. Kassam has over 80 peer reviewed publications, an additional 11 book-chapters currently published or in press, and is funded by both industry and the NIH. He lectures extensively nationally and internationally on surgery of the cranial nerves, skull base and on minimally invasive endoscopic techniques.

Walter Kucharczyk

Walter Kucharczyk was born, raised and educated in Toronto. He graduated from the University of Toronto’s Faculty of Medicine in 1979, after which he undertook specialty training in Radiology in Toronto, followed by subspecialty training in Neuroradiology and Magnetic Resonance Imaging at the University of California, San Francisco from 1984 to 1986. He returned to a faculty position at the University of Toronto in 1986, and became the inaugural Director of Magnetic Resonance Imaging at what was then the Toronto General Hospital. He has remained Director of MRI ever since. At the University, he became Professor and Chair of the Department of Medical Imaging in 1991, a position he has held until today. He is Past-President of the International Society of Magnetic Resonance in Medicine (ISMRM), the largest research and education group in the world (5000 members) devoted to developing and teaching magnetic resonance to doctors and scientists.

During the past 10 years, Dr. Kucharczyk’s research has focused on developing and applying modern high-speed 3D imaging technologies for non-invasive and minimally invasive treatment. He has been awarded several multi-million dollar grants from Technology Ontario (the predecessor of...
**PLENARY GUEST SPEAKERS**

ORDCF), the Canadian Foundation for Innovation, the Ontario Research and Development Challenge Fund (CFI), and most recently, the Leading Edge Fund of CFI. Starting in 1997, he has worked closely with key UHN co-investigators, especially Dr. Mark Bernstein in Neurosurgery and Dr. John Trachtenburg in Urology, to bring these innovative methods to the patient.

Dr. Kucharczyk has led the Toronto University Health Network in a multidisciplinary, multi-institutional, $33M CFI grant (Functional Imaging Research Network) that has been a foundation for MRI research and image guidance therapy research at UHN for the past 7 years. In a related program, he has also been PI and co-led a $25M ORDCF grant for the Ontario Consortium of Image Guided Therapy and Surgery (OCITS). He is one of three provincial leaders in the OCITS consortium. Two years ago he became a Project Leader of the UHN “Guided Therapeutics” Programme and co-leader of the new $25M UHN initiative “The operating room of the future” in which image-guided therapy will play a prominent role.

He published several of the early papers on the design, operation, and treatment of novel Interventional MRI systems to guide conventional “open” surgical procedures, as well as research-based novel percutaneous and transcutaneous heat ablative systems. He published several of the early papers on MR thermometry to monitor, in a spatially localized manner, the effects of heat ablation on human cancer in vivo, including the only publications in the world on microwave ablation with MR thermometry for the treatment of recurrent prostate cancer.

**Michael Shevell**

Dr. Shevell is a pediatric neurologist at the Montreal Children’s Hospital and a Professor (with Tenure) in the Departments of Neurology/Neurosurgery and Pediatrics at McGill University. He holds a subspecialty certification in neurodevelopmental disabilities. A former Chercheur Boursier Clinicien of the FRSQ he has an active research program focusing on issues related to neonatal neurology, children with or at risk for neurodevelopmental sequelae, in particular cerebral palsy, global developmental delay and developmental language impairment. He has presently over 130 publications and 40 book chapters-invited papers. He currently serves on four editorial boards (Canadian Journal of Neurological Sciences, Pediatric Neurology, Journal of Child Neurology and Seminars in Pediatric Neurology). He was the lead author on the American Academy of Neurology/Child Neurology Society Practice Parameter on global developmental delay. He is currently Director of the Quebec Cerebral Palsy Registry. A former President of the Canadian Association of Child Neurology he presently serves on the Executive Board of the International Child Neurology Association and has been Chair of the Ethics Committee of the Child Neurology Society for the past decade. He was Chairman of the recent Xth World Congress of the International Child Neurology Association held in Montreal in June 2006.

**Stephen Ashwal**

Dr. Stephen Ashwal is Distinguished Professor and Chief of the Division of Child Neurology in the Department of Pediatrics at Loma Linda University School of Medicine. He is a graduate of New York University School of Medicine (1966-70), and completed his residency training programs in Pediatrics (Bellevue Hospital, 70-73) and in Child Neurology (University of Minnesota, 73-76). His research activities have focused on critical care issues in child neurology related to brain death, the vegetative and minimally conscious states, bacterial meningitis, and near drowning; the role of nitric oxide in focal cerebral ischemia; development of animal models of neonatal stroke and the use of proton spectroscopy for outcome prediction after acute CNS injuries. He has been a member of the Child Neurology Society since 1975 and served as chair of the Scientific Selection, Ethics, Archives and Practice Committee, Councilor from the West, Secretary-Treasurer of the Society, and President (2001-03). Dr. Ashwal edited The Founders of Child Neurology, published on behalf of the Society in 1990, that is a history of the field of child neurology and its major contributors. He served as co-chair (representing the CNS) on The Multi-Society Task Force on the Persistent Vegetative State. He has been active in the development of practice parameters related to child neurology and served as a member of the Quality Standard Subcommittee of the American Academy of Neurology that is responsible for development of guidelines dealing with issues related to the evaluation of children with autism, cerebral palsy, developmental delay, headaches and status epilepticus. With Dr. Kenneth Swaiman and Dr. Donna Ferriero, he served as coeditor of one of the main textbooks in the field of child neurology, Pediatric Neurology: Principles & Practice (2005).

**Andres M. Lozano**

Dr. Lozano obtained his MD degree from the University of Ottawa and his PhD in Neurobiology from McGill University. He was appointed to the neurosurgical faculty at the University of Toronto in 1991 and became full Professor in 1999. He is currently Professor and RR Tasker Chair in Functional Neurosurgery and holds a Canada Research Chair in Neuroscience at the University of Toronto.

Dr. Lozano’s research is focused on understanding the cellular pathogenesis and developing novel treatments, including surgical therapies for neurological and psychiatric disorders such as Parkinson’s disease, dystonia and depression. His work has appeared in over 250 peer-reviewed publications and he has been invited lecturer or visiting professor throughout the world. He serves on the board and executive of several international organizations and is currently President of the World Society for Stereotactic and Functional Neurosurgery, and Chairman of the Stereotactic and Functional Neurosurgery Section of the World Federation of Neurosurgical Societies. He serves the international editorial board of ten journals and has received a number of awards including the Gold Medal of the Royal College of Physicians and Surgeons of Canada and the Penfield Award.
Michael Bliss

Michael Bliss held the elite title of University Professor when he retired in 2006 after a long career at the University of Toronto. Formally University Professor Emeritus, he is an independent scholar and writer, based in Toronto and Prince Edward Island. He specializes in the history of medicine and the history of Canada. His twelve books (including A Canadian Millionaire, The Discovery of Insulin, Banting, Northern Enterprise, Plague, Right Honourable Men, William Osler, A Life in Medicine, and Harvey Cushing: A Life in Surgery) have received numerous honours, including all the major prizes awarded by the Canadian Historical Association, two City of Toronto Book Awards, two Jason Hannah Medals for medical history from the Royal Society of Canada, the Welch Medal of the American Association for the History of Medicine, and the National Business Book Award.

Professor Bliss was appointed a Member of the Order of Canada in 1999, and elected a Fellow of the Royal Society of Canada in 1984. The Royal Society awarded him its Tyrrell Medal in 1988 “for outstanding work in the history of Canada”. At the time of his retirement, Maclean’s, Canada’s national newsmagazine, referred to him as “perhaps Canada’s greatest living historian.”

Michael Bliss was born in 1941, married in 1963, and has three children. He has been awarded Honorary Doctor of Letters degrees from McGill University and McMaster University and is an Honorary Fellow of the Royal College of Physicians and Surgeons of Canada.

Charles Haw

Charles Haw is an assistant professor in the Department of Surgery, Division of Neurosurgery, University of British Columbia. He completed his medical school and residency training at the University of British Columbia. Subsequently, he travelled to Toronto where he had two and a half years training in interventional neuroradiology. Currently he performs fairly general neurosurgery with a heavy concentration in the surgical and endovascular management of vascular disorders. While he enjoys treating dural fistulas, which will be the topic of his lecture, he realizes that life does not start and end in a shunting zone.

Educational Objectives for the 2007 Congress:

By the end of the Congress the participants will be able to:

- Discuss the advances in the diagnosis and management of acute and chronic neurological diseases
- Review new treatment options for neurosurgical illnesses
- Explore advances in neurobiology
- Assess the consequences of neurological injury in the newborn
Boehringer Ingelheim (Canada) Ltd. proudly supports the Canadian Neurological Sciences Federation Annual Congress as a Platinum Sponsor.

Boehringer Ingelheim (Canada) Ltd. is committed to cerebrovascular and cardiovascular protection research.
Our Vision:
With passion, purpose and partnerships, we transform scientific discoveries into advances in human healthcare.

As a platinum sponsor, Biogen Idec Canada is proud to support the 2007 Congress of the Canadian Neurological Sciences Federation
Neurobiology Review Course  

Course generously supported through an unrestricted educational grant from the Canadian Neurological Society Foundation.

Chair: Jack Jhamandas

Learning Objectives:  
At the completion of this symposium, participants will be able to:
1. Describe the neurobiology of neurodengenerative disease.
2. Reflect upon the neural basis for rhythmic behaviour in the CNS
3. Articulate the neuroimmununology and neuroimaging of Multiple Sclerosis
4. Review the mechanisms and pathphysiology of epilepsy

Target Audience: Clinicians from allied Neuroscience disciplines (neurologists, neurosurgeons, neurophysiologists, etc.) and trainees (residents, fellows, etc.)

FUNDAMENTAL MECHANISMS OF NEURODEGENERATIVE DISEASES
08:00 Neurobiology of the Prion Protein Family
.............................................................................David Westaway, (Edmonton, AB)
08:45 Molecular Basis of Memory Loss in Transgenic Models of Alzheimer's Disease
.............................................................................Karen Hsiao Ashe, (Minnesota, USA)
09:30 Discussion
09:45 Break

NEURAL BASIS FOR RHYTHMIC BEHAVIOR IN THE CNS
10:00 Central Control of Respiratory Rythmogenesis
.............................................................................John Greer, (Edmonton, AB)
10:45 Recent Advances in the Neurobiology of Walking
.............................................................................Keir Pearson, (Edmonton, AB)
11:30 Discussion
12:00 Lunch break

UPDATE ON NEUROIMMUNOLOGY AND NEUROIMAGING OF MULTIPLE SCLEROSIS
13:15 Autoimmunity in Multiple Sclerosis: A double-edged sword
.............................................................................Fabrizio Giuliani, (Edmonton, AB)
14:00 MRI Based Biomarkers of Pathology in Multiple Sclerosis
.............................................................................Ross Mitchell, (Calgary, AB)
14:45 Discussion

EPILEPSY: INSIGHTS INTO PATHOPHYSIOLOGY
15:00 Studying the functional anatomy of the limbic system through temporal lobe epilepsy and magnetic resonance imaging
.............................................................................Don Gross, (Edmonton, AB)
15:45 Mechanisms of Epilepsy
.............................................................................William Colmers, (Edmonton, AB)
16:30 Discussion and evaluation
ALS Strategies for Quality of Life/Quality Care

Chair: David Cameron, Cathy Martin

Learning Objectives: At the completion of this symposium participants will be able to:
1. Describe the current clinical and pathophysiological features of ALS.
2. Identify and apply strategies to improve the function and quality of life for people with ALS.
3. Demonstrate an understanding of research initiatives and findings in ALS.

Target Audience: Interactive full day sessions with patients, caregivers, allied health professionals, neurologists, physiatrists, community support agencies: a comprehensive review of current topics in ALS including diagnosis and research, management and advocacy.

08:30 Registration
09:00 Welcome.........................................................................................David Cameron, (Toronto, ON); Cathy Martin, (Edmonton, AB)

SESSION I PLENARY PRESENTATION - CHAIRS: COLLEEN O'CONNELL, SANJAY KALRA
09:10 Update - Advances in clinical care ...............................................................Michael Strong, (London, ON)
09:35 Update - Advances in basic science ...........................................................Denise Figlewicz, (Toronto, ON)
10:00 Question and answer session
10:20 Break

SESSION II PANEL PRESENTATION - CHAIR: TESSA GORDON
10:40 Patient Perspective..................................................................................TBC
11:00 ALS Society of Alberta.............................................................................TBC
11:20 Environmental risk factors.......................................................................Chris White, (Calgary, AB)
11:40 Managing excessive saliva: drugs, botox, radiation.........................Stuart Cleary, (Edmonton, AB)
12:00 Question and answer session
12:15 Lunch break

SESSION III BREAKOUT SESSIONS
13:30 Patients, Caregivers and Healthcare Professionals - Moderator: Mary Hatcher
(1) Advanced directives ..................................................................................Melinda Hatfield, SW and Jane Rivest, (Calgary, AB)
(2) Is there value in home visits and telehealth?..................................................Pat Carey, (Edmonton, AB)
(3) Sexuality.......................................................................................................Colleen O’Connell, (Fredericton, NB)

13:30 Physicians and Researchers - Moderator: Tim Doherty
(1) The role of EMG, MUNE and transcranial magnetic stimulation in diagnosis, follow-up and clinical trials .............................................Ming Chan, (Edmonton, AB)
(2) Symptoms management...........................................................................Sanjay Kalra, (Edmonton, AB)
15:00 Break

SESSION IV - CHAIRS: DAVID CAMERON, MARY HATCHER
15:15 Discussing hope with ALS patients and families .......................................Wendy Johnston, (Edmonton, AB)
15:55 Concluding remarks and completion of evaluation forms .................David Cameron, (Toronto, ON); Mary Hatcher, (Halifax, NS)
17:00 Discussion and evaluation
Chair: Jerome Yager, Steve Miller

Learning Objectives: At the completion of this symposium, participants will be able to:
1. List the common causes of neurologic injury in the newborn
2. Describe the neurologic consequences of congenital heart disease, and an understanding of newer techniques of detection
3. Understand causes and outcomes of premature birth
4. Articulate new approaches to therapeutic intervention for the brain injured newborn

Target Audience: Pediatric neurologists, pediatricians, neonatologists, residents, nurses.

08:30 Introduction
08:40 Neonatal brain ischemia: Neuroimaging as a basis for rational stem cell therapy...........Stephen Ashwal, (Loma Linda, CA, USA)
09:40 Neonatal seizures - Do they cause brain damage?..............................................................Lionel Carmant, (Montreal, QC)
10:20 Break
10:50 State of the art neuroimaging and the newborn brain......................................................Steve Miller, (Vancouver, BC)
11:30 A new look at outcomes of infants with congenital heart disease..................................Annette Majnemer, (Montreal, QC)
12:10 Lunch
13:30 Does inflammation matter? ................................................................................................Guillaume Sebire, (Sherbrooke, QC)
14:10 Outcomes in the extremely preterm infant: What’s new and where are we going?...........Charlene Robertson, (Edmonton, AB)
14:50 Therapeutic interventions for the newborn: Do we have anything to offer? ......................Jerome Yager, (Edmonton, AB)
15:40 Break
16:00 Case reports
16:30 Discussion and evaluation
Epilepsy Video Session

Chair: Richard McLachlan

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Understand how to best utilize videos to diagnose paroxysmal events
2. Explore the electro –clinical features of neuro-metabolic seizures
3. Review the use of videos in the pediatric population

Target Audience: Residents, fellows and students. Adult and pediatric neurologists, neurology nurses and EEG technologists.

18:00 Electroclinical features of neurometabolic causes of epilepsy .................................................Mary Connolly, (Vancouver, BC)
18:15 Discussion
18:25 Epilepsy in the land of milk and honey .............................................................................................Sam Wiebe, (Calgary, AB)
18:45 Discussion
18:55 Pediatric epilepsy .................................................................................................................................Sharon Whiting, (Ottawa, ON)
19:15 Discussion
19:25 Something of interest to everyone .................................................................................................Richard McLachlan, (London, ON)
19:55 Discussion and evaluation

Movement Disorders Management: Drugs to Surgery

Chair: Richard Camicioli

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Understand the available evidence based approaches to the treatment of Parkinson’s disease
2. Identify candidates for surgical assessment for parkinsonism and hyperkinetic movement disorders and be aware of realistic outcomes and risks
3. Review the evidence based treatment for chorea, dyskinesia and dystonia

Target Audience: TBC

18:00 Medical management of Parkinsonism .................................................................................................Oksana Suchowersky, (Calgary, AB)
18:25 Surgical management of Parkinsonism ...............................................................................................Christopher Honey, (Vancouver, BC)
18:55 Medical management of Chorea and Dystonia ..................................................................................Mandar Jog, (London, ON)
19:25 Surgery of hyperkinetic movement disorders ....................................................................................Andres Lozano, (Toronto, ON)
19:55 Discussion and evaluation

SPECIAL INTEREST GROUPS

18:00 ALS ..................................................................................................................................................Jasper Room Fairmont Angela Genge
18:00 NEUROMUSCULAR .............................................................................................................................Salon 3 Mike Nicolle
18:00 NEUROSURGERY RESIDENTS’ EDUCATION .................................................................................Drawing Room Fairmont Brian Toyota
18:00 UNDERGRADUATE NEUROLOGICAL EDUCATION ...........................................................................Salon 13 & 14 Kevin Busche
Grand Opening Plenary: Scientific and Technical Advances in the Clinical Neurosciences  

**Salon 12**  
08:30-10:30

**Chairs:** Mark Hamilton, Andrew Kirk

**Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Discuss contemporary imaging techniques in neurological disorders
2. Articulate neurosurgical treatment options for psychiatric disorders
3. Describe the utilization of advanced neuron-imaging techniques for pediatric traumatic brain injury

08:30  Welcome and Introduction

08:45  **Contemporary imaging techniques in neurological disorders** .............................................Walter Kucharczyk, (Toronto, ON)*

09:20  **Contemporary neurosurgical approaches to the treatment of psychiatric disorders** ................Andres Lozano, (Toronto, ON)*

09:55  **Tibbles Lecture - Pediatric traumatic brain injury: Normal appearing brain is not normal - Use of advanced neuroimaging techniques** .................................................................Steve Ashwal, (Loma Linda, CA, USA)*

* Sponsored by the Royal College of Physicians and Surgeons of Canada.

---

**Chair’s Select Plenary Presentation**  

**Salon 12**  
10:45-12:15

**Neuropathic Pain - Pathophysiology, Prevention and Management**  

**Drawing Room Fairmont**  
14:00-17:30

*Course generously supported through an unrestricted educational grant from Pfizer Inc.*

**Chair:** Dwight Moulin

**Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Understand the pathophysiology of neuropathic pain as a basis for treatment
2. Provide an evidence based approach to the management of neuropathic pain
3. Appreciate the value of novel agents in the prevention and management of neuropathic pain

**Target Audience:** Family doctors, neurologists, neurosurgeons and clinical nurse practitioners.

14:00  **Prevalence and pathophysiology of neuropathic pain** ..........................................................Dwight Moulin, (London, ON)

14:30  Discussion

14:45  **Post-herpetic neuralgia - assessment and management** ...............................................................Peter Watson, (Toronto, ON)

15:15  Discussion

15:30  Nutrition Break

15:45  **Evidence-based guidelines for the management of neuropathic pain** ............................................Dwight Moulin, (London, ON)

16:30  **Novel agents in the management of neuropathic pain - cannabinoids and beyond** ....................John Clark, (Calgary, AB)

17:00  Discussion and evaluation
Spine Course - The Triage and Management of the Cervical Spondylotic Myelopathy Patient

Wedgewood Fairmont - 14:00-17:30

Chair: Eric Massicotte

Learning Objectives:

1. Appreciate and understand the challenges of assessing the patients with myelopathy. List clues that can assist in the accurate diagnosis
2. Discuss management options in this patient population
3. Review specific surgical approaches for the spondylitic patients
4. Articulate the role of minimally invasive and reconstructive techniques in this patient population

Target Audience: Neurologists and neurosurgeons both in training and in established practices along with health care providers can benefit from this session.

14:00 Diagnostic challenges: What are the clinical clues? ..................................................................................................................Robert Chen, (Toronto, ON)
14:15 Discussion
14:30 Natural history of spondylosis and myelopathy .........................................................................................................................Richard Fox, (Edmonton, AB)
14:45 Discussion
15:00 Anterior approaches to cervical spondylosis .............................................................................................................................Steve Casha, (Calgary, AB)
15:15 Discussion
15:30 Posterior approaches to cervical spondylosis .............................................................................................................................Ramesh Sahjpaull, (Vancouver, BC)
15:45 Discussion
16:00 Break
16:15 Role of minimally invasive techniques .............................................................................................................................................Sean Christie, (Halifax, NS)
16:30 Discussion
16:45 Complex reconstruction strategies ..................................................................................................................................................Eric Massicotte, (Toronto, ON)
17:00 Functional outcome of cervical spondylotic myelopathy .......................................................................................................Sukhuinder Kalsi-Ryan, (Toronto, ON)
17:10 Discussion and evaluation
**Clinical Electromyography Course**

*Course generously supported through an unrestricted educational grant from Roxon Medi-Tech and XLTEK.*

Workshop 1, 2, and 4 will be held at the Shaw Centre. Workshop 3 will be held at the University of Alberta [No transportation provided]. There will be 2 sessions of 1, 2, and 4 only.

**Chairs:** Ming Chan, Joseph Chu

**Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Understand the electrodiagnostic approach to ALS and look-alikes
2. Review the single fiber EMG
3. Describe the electrodiagnostic tests and identification of uncommonly studied nerves of the upper extremity
4. Discuss the EMG pearls and pitfalls especially when studying unusual muscles

**Target Audience:** Neurologists, EMGers, neurology fellows and residents, physiologists and EMG technicians.

14:00 & 16:00
**Workshop I:** Electrodiagnostic approach in the work-up of ALS and look-alikes............Salon 15 Chris White, (Calgary, AB)

14:00 & 16:00
**Workshop II:** Single fibre EMG.....................................................................................Salon 16 Michael Nicolle, (London, ON)

14:00
**Workshop III:** Anatomic identification and electrodiagnostic testing of uncommonly studied nerves in the upper limb....

University of Alberta Lalith Satkunam, (Edmonton, AB); Ian Grant, (Halifax, NS); Michael Morhart, (Edmonton, AB)

14:00 & 16:00
**Workshop IV:** EMG of unusual muscles and their relevance to electrodiagnosis in neurology
.........................................................................................................................Salon 19 Jasper Daube, (Rochester, MN, USA)

**Stroke Course**

*Course generously supported through an unrestricted educational grant from Sanofi-aventis/Bristol-Myers Squibb.*

**Chairs:** Khurshid Khan, Ashfaq Shuaib

**Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Analyze the pathophysiological mechanisms contributing to atherosclerosis and various types of stroke
2. Explore in detail the various new imaging technologies that help a diagnosis in stroke
3. Identify the best treatment options for specific stroke sub-types
4. Critically assess new emerging therapies in cerebral vascular disease

**Target Audience:** Neurologists, neurosurgeons and other health care professionals involved in the treatment of patients with cerebrovascular disease.

14:00
**Acute stroke management........................................................................................................Philip Teal, (Vancouver, BC)**

14:25 Discussion

14:35 **Stroke prevention............................................................................................................Ashfaq Shuaib, (Edmonton, AB)**

15:00 Discussion

15:10 **Neuroimaging (CT/MRI) in acute stroke........................................................................Ken Butcher, (Edmonton, AB)**

15:35 Discussion

15:40 Break

15:50 **Intracerebral hemorrhage............................................................................................Matthew Hogan, (Ottawa, ON)**

16:15 Discussion

16:25 **Neurosurgical approach to “asymptomatic” cerebrovascular conditions (including carotid disease, aneurysms and vascular malformations).................................................................................................................................................................Max Findley, (Edmonton, AB)**

16:50 Discussion

17:00 **Endovascular procedures.........................................................................................Michael Chow, (Edmonton, AB)**

17:25 Discussion and evaluation
**Epilepsy Course: Intractable Epilepsy**

**Chair:** Richard Wennberg

**Learning Objectives:** At the completion of this symposium, participants will be able to:

1. Identify patients with intractable epilepsy
2. Assess the burden of intractable epilepsy in Canada
3. Understand when and why to refer patients to specialized epilepsy centers
4. Understand the pre-surgical investigations and outcomes of epilepsy surgery in children and adults

**Target Audience:** Adult and pediatric neurologists and neurosurgeons, residents and fellows in neurology or neurosurgery, epileptologists and allied healthcare workers in epilepsy.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker (City, AB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>14:10</td>
<td><strong>Adult intractable epilepsy: Clinical overview and investigations</strong></td>
<td>Don Gross, (Edmonton, AB)</td>
</tr>
<tr>
<td>14:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:35</td>
<td><strong>Adult intractable epilepsy: Epidemiology and economic burden</strong></td>
<td>Sam Wiebe, (Calgary, AB)</td>
</tr>
<tr>
<td>14:55</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td><strong>Adult intractable epilepsy: Surgery</strong></td>
<td>Andrew Parrent, (London, ON)</td>
</tr>
<tr>
<td>15:20</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:25</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>15:40</td>
<td><strong>Neuroimaging in intractable epilepsy</strong></td>
<td>Andrea Bernasconi, (Montreal, QC)</td>
</tr>
<tr>
<td>16:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:05</td>
<td><strong>Development of a comprehensive epilepsy centre</strong></td>
<td>Taufik Valiente, (Toronto, ON)</td>
</tr>
<tr>
<td>16:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Pediatric intractable epilepsy: Clinical overview and investigations</strong></td>
<td>Mary Connolly, (Vancouver, BC)</td>
</tr>
<tr>
<td>16:50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:55</td>
<td><strong>Pediatric intractable epilepsy: Surgery</strong></td>
<td>James Rutka, (Toronto, ON)</td>
</tr>
<tr>
<td>17:15</td>
<td>Discussion and evaluation</td>
<td></td>
</tr>
</tbody>
</table>

**Neurocritical Care Course**

**Chairs:** Draga Jichici, Jeanne Teitelbaum

**Learning Objectives:** At the completion of this symposium, participants will be able to:

1. Apply hypothermia treatment in selected patient groups
2. Treat effectively status epilepticus
3. Understand the mimickers of brain death
4. Assess and diagnose neuromuscular weakness in the ICU setting
5. Review new techniques in the diagnosis and management of traumatic brain injury
6. Prognosticate outcome following cardiac arrest

**Target Audience:** Practicing neurologists, neurosurgeons, critical care physicians, residents and nurses.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker (City, AB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>The management of status epilepticus</strong></td>
<td>Martin Savard, (London, ON)</td>
</tr>
<tr>
<td>14:30</td>
<td><strong>Hypothermia in Neurocritical Care: When to use it</strong></td>
<td>Draga Jichici, (Hamilton, ON)</td>
</tr>
<tr>
<td>15:15</td>
<td><strong>New approaches to generalized weakness in the ICU</strong></td>
<td>Charles Bolton, (Kingston, ON)</td>
</tr>
<tr>
<td>15:45</td>
<td><strong>Brain Death: Or is it?</strong></td>
<td>Jeanne Teitelbaum, (Montreal, QC)</td>
</tr>
<tr>
<td>16:15</td>
<td><strong>What’s new in management of traumatic brain injury: Microdialysis</strong></td>
<td>David Zygun, (Calgary, AB)</td>
</tr>
<tr>
<td>16:45</td>
<td>Discussion and evaluation</td>
<td></td>
</tr>
</tbody>
</table>
Plenary Session: CNS, CACN, and CSCN Neurology

Chair: Richard Desbiens

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Discuss new developments in the management of inflammatory myopathies
2. Understand the causes and life course of persons born with “cerebral palsy”, and the broad principles of managing such patients

08:30 Welcome and Introduction
08:35 Gloor Lecture - Inflammatory myopathies - New developments ..........................................................................................................................Tony Amato, (Boston, MA, USA)
09:20 Richardson Lecture - A Moving Target: Contemporary challenges in Cerebral Palsy across the lifespan .................................................................................................................Michael Shevell, (Montreal, QC)

Plenary Session: CNSS Neurosurgery

Chair: Derek Fewer

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Understand the principles of endoscopic neurosurgery
2. Review the outcomes and complications of endoscopic neurosurgery
3. Discuss the surgical and endovascular treatment of dural arteriovenous fistulas

08:30 Welcome and Introduction
08:35 Penfield Lecture - Principles of Endoscopic Neurosurgery: Outcomes and Complications over a Decade and 700 Patients .................................................................................................................Amin Kassam, (Pittsburgh, PA, USA)
09:20 Surgical and endovascular management of cranial and spinal dural arteriovenous fistulas .........Charles Haw, (Vancouver BC)

Platform Sessions (6 concurrent)

Lunch / Digital Poster and Exhibit Viewing

Platform Sessions (7 concurrent)

Digital Poster and Exhibit Viewing
Distinguished Guest Lecturer  

Plenary generously supported through an unrestricted educational grant from the Canadian Journal of Neurological Sciences.

**Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Review the history of the development of neurosurgery and neurology
2. Discuss the burden of neurological disease, disorders and injuries in Canada

08:30  Welcome and Introduction
08:40  From Osler to Cushing - The Rise of Medicine, the Rise of Neurosurgery ..........................................................Michael Bliss, (Toronto, ON)

The CBANHC Report  

**Salon 12** - **09:30-09:50**

09:30  The Burden of Neurological Diseases, Disorders and Injuries in Canada..........................................................Charles Tator, (Toronto, ON); Garth Bray, (Montreal, QC)

CJNS Reviewer of the Year Award Presentation & Introduction of the new CJNS Editor  

**Salon 12** - **09:50-10:00**

Digital Poster and Exhibit Viewing  

**Salon 8,9,10,11** - **10:00-10:15**

Grand Rounds  

**Salon 12** - **10:15-12:00**

**Chairs:** Richard Camicioli, Michael Hill

**Learning Objectives:** At the completion of this symposium, participants will be able to:

**Neurology Case:** ..........................................................Taim Muayqil, (Zaeem Sidiqui, Richard Camicioli)

Depression and mild cognitive impairment

**Neurosurgery Case:** ..........................................................Fred Lam, (Matt Wheatley, Wendy Johnston, Ted Roberts)

Motor neuron disease and the neurosurgeon

**Pediatric Neurology Case:** .........................................................Vijay Ramaswamy, (Lawrence Richer, Hanna Kolski)

Bilateral cysts and spontaneous subdural hemorrhage

Lunch / Digital Poster and Exhibit Viewing  

**Salon 8,9,10,11** - **12:00-13:30**
Headache Course

Course generously supported through an unrestricted educational grant from Procter & Gamble.

Chair: Marek Gawel

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Assess contributory factors and etiology in patients with chronic headache
2. Integrate knowledge of pathophysiology and pharmacological causes of chronic headache
3. Establish a multidisciplinary treatment plan
4. Select appropriate pharmacological and non-pharmacological therapies in chronic headache

Target Audience: General neurologists

13:30 Welcome ............................................................................................................. Marek Gawel, (Toronto, ON)
13:45 Recent advances in pathophysiology including recent PET data ........................................ Michael Aubé, (Montreal, QC)
14:00 Patent foramen ovale and CNS white matter lesions in migraine: Current concepts ..... Werner Becker, (Calgary, AB)
14:15 Chronic tension type headache ................................................................. Michael Aubé, (Montreal, QC)
14:45 Transformed Migraine ............................................................................. Lara Cooke, (Calgary, AB)
15:15 Tension type headache in children ............................................................ Shashi Seshia, (Saskatoon, SK)
15:30 Post traumatic headache ........................................................................ Marek Gawel, (Toronto, ON)
16:00 Chronic Cluster and trigeminal autonomic cephalalgias .................................. Suzanne Christie, (Ottawa, ON)
16:30 Discussion and evaluation

What’s New in Neurosurgery Course

Chair: Rick Moulton

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Review management options and outcomes of patients with hydrocephalus
2. Identify emerging therapies and management options for AVMs
3. Articulate novel treatment options and related outcomes in severe brain injury
4. Discuss emerging therapies and management options in the patient with glioma
5. Select appropriate management strategies for spinal metastasis
6. Compare outcomes and treatment options for temporal lobe epilepsy

Target Audience: Neurosurgeons, neurosurgical residents, neurologists

13:30 Hydrocephalus .......................................................................................... Ab Kulkarni, (Toronto, ON)
14:00 AVMs ......................................................................................................... Ian Fleetwood, (Halifax, NS)
14:30 Severe Brain Injury .................................................................................. Rick Moulton, (Ottawa, ON)
15:00 Gliomas ..................................................................................................... Ian Parney, (Calgary, AB)
15:30 Spinal Metastasis .................................................................................... Daryl Fourney, (Saskatoon, SK)
16:00 Temporal lobe epilepsy ........................................................................ Matt Wheatley, (Edmonton, AB)
16:30 Discussion and evaluation

FRIDAY, JUNE 22, 2007

EDMONTON, ALBERTA
EEG Course

Chair: Seyed Mirsattari

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Recognize commonly encountered normal and abnormal EEG patterns in patients with epilepsy
2. Review the characteristics of EEG in the neonate and pediatric population
3. Appreciate the fundamentals of EEG technology including digital technology

Target Audience: Neurologists, neurology residents and pediatric neurologists.

13:30 Neonatal EEG - Normal and abnormal .........................................................Eli M. Mizrahi, (Houston, TX, USA)
14:15 Discussion
14:20 Pediatric EEG ........................................................................................................Warren T. Blume, (London, ON)
15:05 Discussion
15:10 Break
15:15 Adult EEG - Normal and patients with epilepsy ..................................................Richard S. McLachlan, (London, ON)
16:00 Discussion
16:05 Fundamentals of EEG technology, with an emphasis on digital techniques ..................Susan Rahey, (Halifax, NS)
16:50 Discussion and evaluation

Dementia Course

Course generously supported through an unrestricted educational grant from Pfizer Inc.

Chair: Gabriel Léger

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Recognize the common presentations on non-Alzheimer’s dementias (mixed/vascular, Lewy body/Parkinson’s
disease, and frontotemporal) and how the differ from the typical Alzheimer’s disease (AD)
2. Utilize sensitive bedside cognitive testing to help differentiate these dementias from AD
3. Diagnose these dementias based on current consensus diagnostic criteria
4. Determine a treatment plan tailored to the non-Alzheimer’s dementia, including which drugs to use and
which to avoid

Target Audience: Neurologists

13:30 From vascular dementia to vascular cognitive impairment ...........................................Christian Bocti, (Montreal, QC)
14:15 Discussion
14:45 Parkinson’s disease dementia and Lewy body disease ...............................................Céline Chayer, (Montreal, QC)
15:30 Discussion
15:45 Diagnosis and management of the frontotemporal dementias ....................................Gabriel Léger, (Montreal, QC)
16:30 Discussion and evaluation
MS Course

Chair: Kenneth Warren

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Understand the magnitude and character of MS in Canadian society
2. Discuss the qualitative and quantitative changes in cerebrospinal fluid and neuropathological features of MS
3. Review new developments in pathology and pharmacology affecting the management of MS

Target Audience: General neurologists and neurologists who specialize in MS.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>MRI developments</td>
<td>Derrick Emery, Edmonton, AB</td>
</tr>
<tr>
<td>13:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>13:50</td>
<td>Changing demographic and clinical trends</td>
<td>Sharon Warren, Edmonton, AB</td>
</tr>
<tr>
<td>14:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:10</td>
<td>Quality of life</td>
<td>Karen Turpin, Edmonton, AB</td>
</tr>
<tr>
<td>14:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Neuropathological variability</td>
<td>Lothar Resch, Edmonton, AB</td>
</tr>
<tr>
<td>14:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>Neuron loss and neuroprotection</td>
<td>Fabrizio Giuliani, Edmonton, AB</td>
</tr>
<tr>
<td>15:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>New therapeutic developments</td>
<td>Greg Blevins, Edmonton, AB</td>
</tr>
<tr>
<td>15:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:50</td>
<td>Neurovirology</td>
<td>Chris Power, Edmonton, AB</td>
</tr>
<tr>
<td>16:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>Experiences of institutionalized patients</td>
<td>Garry Wheeler, Edmonton, AB</td>
</tr>
<tr>
<td>16:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>CSF antibodies</td>
<td>Ingrid Catz, Edmonton, AB</td>
</tr>
<tr>
<td>16:45</td>
<td>Discussion and evaluation</td>
<td></td>
</tr>
</tbody>
</table>
What's New in Neurology?

Chair: Ashfaq Shuaib

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Discuss new treatment options and management of ALS
2. Review advances in the treatment of infections of the CNS
3. Outline the treatment options and new therapies for CNS tumours
4. Articulate advances in neuromuscular disease
5. Describe existing and novel treatment options for intracranial hemorrhage

Target Audience: Neurologists, neurology residents, nurses, fellows and neurosurgeons.

13:30 Introduction
13:40 What's new in neuromuscular? .................................................................Douglas Zochodne, (Calgary, AB)
14:15 Discussion
14:20 What's new in infections? ........................................................................Chris Power, (Edmonton, AB)
14:55 Discussion
15:00 What's new in intercranial hemorrhage? ..............................................Ashfaq Shuaib, (Edmonton, AB)
15:35 Discussion
15:40 What's new in ALS? .................................................................................Mike Strong, (London, ON)
16:15 Discussion
16:20 What's new in CNS tumours?.................................................................Ian Parney (Calgary, AB)
16:55 Discussion and evaluation
Neuromuscular Course

Chair: Mike Nicolle

Learning Objectives: At the completion of this symposium, participants will be able to:
1. Differentiate and manage common and uncommon entrapment neuropathies
2. Diagnosis disorders affecting the brachial and lumbosacral plexus
3. Explain the relationship between the basic physiology of nerve function and peripheral nerve pathology in diabetes
4. Articulate the clinical manifestations of diabetic neuropathies
5. Integrate knowledge of genetic mechanisms of congenital myotonic dystrophy with the clinical manifestations and diagnostics tests available

Target Audience: Allied health care workers, neurology and physiatry residents and fellows; academic and community neurologists and physiatrists with an interest or learning need in the field of neuromuscular neurology and physiatry.

13:30  Focal peripheral neuropathies: Focus on specific diagnostic and management challenges ........John Stewart, (Vancouver, BC)
14:00  Discussion
14:15  Brachial and lumbosacral plexopathies: Clinical dilemmas and atypical variants ..............Kristine Chapman, (Vancouver, BC)
14:45  Discussion
15:00  Break
15:30  Congenital Myotonic Dystrophy: A review and update from the Canadian Surveillance and Cohort Study ..................................................Craig Campbell, (London, ON)
16:00  Discussion
16:15  Diabetic neuropathy: New directions ....................................................Douglas Zochodne, (Calgary, AB)
16:45  Discussion and evaluation
WINNERS OF THE 2007 SOCIETY PRIZES

THE PRESIDENT’S PRIZE – CANADIAN ASSOCIATION OF CHILD NEUROLOGY

Novel corticospinal tract pre-wallerian degeneration in pediatric stroke: acute MRI prediction of outcome and TMS correlates of reorganization
A Kirton* (Toronto), T Domi (Toronto), R Chen (Toronto), M Shroff (Toronto), C Gunraj (Toronto), E Kouzmatcheva (Toronto), G deVeber (Toronto)

FRANCES MCNAUGHTON MEMORIAL PRIZE – CANADIAN NEUROLOGICAL SOCIETY

Dominantly inherited essential cortical myoclonus in a large Canadian Mennonite family
JL Steckley* (London), G Gibson (Vancouver), A Kirk (Saskatoon), AF Hahn (London)

ANDRE BARBEAU MEMORIAL PRIZE – CANADIAN NEUROLOGICAL SOCIETY

The role of microglia in ALS
L Korngut* (London), L Ang (London), M Strong (London)

HERBERT JASPER PRIZE – CANADIAN SOCIETY OF CLINICAL NEUROPHYSIOLOGISTS

Failure of corticosteroid iontophoresis to treat carpal tunnel syndrome: a double-blind randomized controlled trial
N Amirjani* (Winnipeg), SG Rennie (Edmonton), NL Ashworth (Edmonton), J Watt (Edmonton), T Gordon (Edmonton), K Chan (Edmonton)

K.G. McKENZIE PRIZE IN CLINICAL NEUROSCIENCE RESEARCH – CANADIAN NEUROSURGICAL SOCIETY

The impact of therapeutic modality on outcomes following repair of ruptured intracranial aneurysms: An administrative data analysis
CJ O’Kelly* (Toronto), A Kulkarni (Toronto), P Austin (Toronto), D Urbach (Toronto), M Wallace (Toronto)

K.G. McKENZIE PRIZE IN BASIC NEUROSCIENCE RESEARCH – CANADIAN NEUROSURGICAL SOCIETY

Enhancement of sensorimotor behavioural recovery in parkinsonian rats with a multitarget basal ganglia dopaminergic and GABAergic transplantation strategy
K Mukhida* (Halifax), M Hong (Halifax), M McLeod (Halifax), G Miles (Halifax), N Kobayashi (Halifax), Baghbaderani (Calgary), A Sen (Calgary), L Behie (Calgary), R Brownstone (Halifax), I Mendez (Halifax)
Chair's Select Plenary Presentations

Chairs: John Stewart, Mike Tymianski

Salon 12

A-01 Prospective error recording in surgery: an analysis of 1108 elective neurosurgical cases
SS Stone* (Toronto), M Bernstein (Toronto)

A-02 Epilepsy surgery in children under 3 years of age: A Canadian wide survey
P Steinbok* (Vancouver), YC Gan (Vancouver), MB Connolly (Vancouver), L Carmant (Montreal), B Sinclair (Edmonton), J Rutka (Toronto), R Griebel (Saskatoon), K Aronyk (Edmonton), W Hader (Calgary), E Ventureyra (Ottawa)

A-03 The impact of therapeutic modality on outcomes following repair of ruptured intracranial aneurysms: An administrative data analysis.
CJ O'Kelly* (Toronto), A Kulkarni (Toronto), P Austin (Toronto), D Urbach (Toronto), M Wallace (Toronto)

A-04 STN-DBS for Parkinson's disease: variation in outcomes and adverse effects
P Itthimethin* (Calgary), K Doig-Beyaert (Calgary), K Hunka (Calgary), O Suchowersky (Calgary), S Kraft (Calgary), Y Starreveld (Calgary), M Kwan (Calgary), ZH Kiss (Calgary)

A-05 Dominantly inherited essential cortical myoclonus in a large Canadian Mennonite family
JL Steckley* (London), G Gibson (Vancouver), A Kirk (Saskatoon), AF Hahn (London)

A-06 Failure of corticosteroid iontophoresis to treat carpal tunnel syndrome: a double-blind randomized controlled trial
N Amirjani* (Winnipeg), SG Rennie (Edmonton), NL Ashworth (Edmonton), J Watt (Edmonton), T Gordon (Edmonton), K Chan (Edmonton)

General Neurosurgery I

Chair: Taufik Valiante

Salon 4

B-01 Intraoperative monitoring of cochlear nerve function
DW Rowed* (Toronto), DA Houlden (Toronto)

B-02 ETV (Endoscopic third ventriculostomy) does ventricular size correlate with clinical outcome?
G Lapointe* (Quebec), M Lapointe (Quebec), A Turmel (Quebec)

B-03 A prospective study of awake craniotomy used routinely and non-selectively for supratentorial tumors
D Serletis (Toronto), M Bernstein* (Toronto)

B-04 Visual fields are preserved in acromegalic patients treated with SRT
IG Fleetwood* (Halifax), DB Clarke (Halifax), L Clarke (Halifax), S Imran (Halifax), E Ur (Halifax), DE Rheaume (Halifax), LA Mulroy (Halifax)

B-05 Histopathological examination in routine discectomy: a cost-benefit analysis
AS Wu* (Saskatoon), DR Fourney (Saskatoon)

B-06 High grade glioma in Canada: are there regional differences?
JF Megyesi* (London), C DeSilva* (London)

B-07 Early neurosurgical intervention in the management of central nervous system blastomycosis
G Marchuk* (Winnipeg), M Del Bigio (Winnipeg), S Krawitz (Winnipeg), J Embil (Winnipeg), P McDonald (Winnipeg)

B-08 The role of recombinant activated factor VII in neurosurgery: hope or hype?
GW Hawryluk* (Toronto), MD Cusimano (Toronto)

General Neurology I

Chair: Peter Bailey

Salon 12

C-01 White matter high signal changes in Parkinson's disease: risk factors and correlates
RCamicioli* (Edmonton), WW Martin (Edmonton), T Bouchard (Edmonton), T Green (Edmonton), C Hanstock (Edmonton), N Fisher (Edmonton), D Emery (Edmonton)

C-02 Magnetic resonance imaging of progressive multifocatal leukoencephalopathy in HIV positive patients
T Nguyen* (Ottawa), F Al Azri (Ottawa), C Lum (Ottawa), W Miller (Ottawa), M Kingstone (Ottawa), J Wolfe (Ottawa), G Jensen (Ottawa)
C-03  Neuropathic pain is common, disabling, and greatly impairs quality of life and earning potential in Albertans: a population-based survey
C Toth* (Calgary), J Lander (Edmonton)

C-04  Occipital condyle syndrome as the first presentation of disseminated malignancy: two cases and a review of the literature
JJ Moeller* (Halifax), S Shivakumar (Halifax), M Davis (Halifax), CE Maxner (Halifax)

C-05  Facial nerve pathology associated with cluster headache
DW Rowed* (Toronto), JJ Edmeads (Toronto)

C-07  Neurology in the developing world: developing a Canadian perspective
P Bailey* (Saint John), M Freedman (Toronto), A Kirk (Saskatoon), M Beaulieu (Ottawa), R Desbiens (Quebec), JC Martin del Campo (Toronto)

C-08  Cerebral venous thrombosis in Singapore, 1994-2007
H Chua* (Singapore), J Chai (Singapore)

GENERAL PEDIATRIC NEUROLOGY

CHAIR: ELAINE WIRRELL  SALON 5&6

D-01  Neonatal Arterial Ischemic Stroke in the Canadian Registry
G deVeber* (Toronto), C Group (Toronto)

D-02  Novel corticospinal tract pre-wallerian degeneration in pediatric stroke: acute MRI prediction of outcome and TMS correlates of reorganization.
A Kirton* (Toronto), T Domi (Toronto), R Chen (Toronto), A Shroff (Toronto), C Gunraj (Toronto), E Kouzmatcheva (Toronto), G deVeber (Toronto)

D-03  Decompressive hemicraniectomy for malignant hemispheric infarction in children
V Ramaswamy* (Edmonton), V Mehta (Edmonton), LP Richer (Edmonton), P Massicotte (Edmonton), JY Yager (Edmonton)

D-04  Neuroimaging challenges in the diagnosis of pediatric arterial ischemic stroke
A Pontigon (Toronto), M Rafay* (Winnipeg), J Chiang (Toronto), A Jarvis (Toronto), A Jarvis (Toronto), F Silver (Toronto), G deVeber (Toronto)

D-05  Chronic daily headache (CDH) in children and adolescents: a prospective Saskatchewan study
SS Seshia* (Saskatoon), DF Phillips (Saskatoon), CL von Baeyer (Saskatoon)

D-06  Head and neck infections in children with cerebral sinovenous thrombosis
L Billinghurst* (Edmonton), G deVeber (Toronto)

D-07  Symptomatic white matter injury following methotrexate treatment in childhood
N Makhan* (Toronto), J Hukin (Vancouver)

D-08  Gestational diabetes mellitus: risk of newborn brain injury
N Lynch* (Vancouver), EH Roland (Vancouver), K Poskitt (Vancouver), S Miller (Vancouver), M Sargent (Vancouver), A Hill (Vancouver)

D-09  A phenomenological study on parental experience in pediatric neuromuscular disorders
JK Mah* (Calgary), D McNeil (Calgary), J Thannhauser (Calgary), H Kolski (Edmonton), D Dewey (Calgary)

STROKE

CHAIR: GORDON GUBITZ  SALON 3

E-01  The Transcranial Doppler (TCD) flow finding at the site of occlusion predicts response to intravenous stroke thrombolysis
M Saqqur* (Edmonton), G Tsivgoulis (Phoenix), AM Demchuk (Calgary), CM Molina (Barcelona), A Shuaib (Edmonton), AV Alexandrov (Phoenix)

E-02  Magnetic resonance molecular imaging of endothelial activation in acute stroke
AY Jin* (Calgary), D Rushforth (Calgary), R Filfil (Montreal), J Kaur (Calgary), F Ni (Montreal), B Tomanek (Calgary), U Tuer (Calgary), PA Barber (Calgary)

E-03  Matrix metalloproteinase-3 is neurotoxic in cell culture and in intracerebral hemorrhage in mice
M Xue* (Calgary), V Yong (Calgary)
E-04  Multiple interventions for neuroprotection utilizing thermal-regulation in the emergent treatment of stroke: the MINUTES study
MM Siddiqui* (Edmonton), Y Ludwig (Edmonton), Y Bhagat (Edmonton), MS Hussain (Edmonton), A Mateer (Edmonton), D Manawadu (Edmonton), M Saqqur (Edmonton), C Beaulieu (Edmonton), A Shuaib (Edmonton)

E-05  The Combination of Clinical features, Transcranial Doppler and ASPECTS score in predicting outcome in IV rt-PA treated patients
S Husain* (Edmonton), AV Alexandrov (Phoenix), AM Demchuk (Calgary), G Tsivgoulis (Phoenix), A Shuaib (Edmonton), M Saqqur (Edmonton)

E-06  Quantified T1 and T2 as useful adjuncts to DWI for early infarct detection in permanent and transient MCAO
J Kaur* (Calgary), U Tuor (Calgary), Z Zhao (Calgary), H Assem (Calgary), J Lee-Petersen (Calgary), T Fonik (Calgary), P Barber (Calgary)

E-07  Intracranial nonocclusive thrombus on CT angiography: reason to be concerned?
V Puetz* (Calgary), I Dzialowski (Dresden), S Subramaniam (Calgary), A Krol (Calgary), AM Demchuk (Calgary)

E-09  Rapid cognitive improvement in a patient with Susac Syndrome following plasma exchange: a case report
FJ Mateen* (Rochester), A Zubkov (Rochester), GW Petty (Rochester), J Fulgham (Rochester)

MULTIPLE SCLEROSIS

CHAIR: Luanne Metz  

F-01  T1 Gd-enhancing lesion number and new T2 number are reduced when minocycline is combined with glatiramer acetate
LM Metz* (Calgary), D Li (Vancouver), A Trabousee (Vancouver), M Myles (Edmonton), P Duquette (Montreal), J Godin (Montreal), M Constantin (Montreal), VW Yong (Calgary)

F-02  The Geospatial Relation between ultraviolet radiation and multiple sclerosis in Newfoundland
S Sloka* (St John’s), WE Pryse-Phillips (St John’s), M Stefanelli (St John’s)

F-03  Neuroprotection by minocycline occurs without the intermediary of microglia
S Liu* (Calgary), E O’Ferrall (Calgary), W Yong (Calgary)

F-04  1000 IU of daily vitamin D is usually too little to attain a minimally adequate 25-hydroxyvitamin D level in Multiple Sclerosis patients
P Ahluwalia* (Calgary), L Metz (Calgary), R Bell (Calgary), D Patry (Calgary), W Murphy (Calgary), D McGowan (Calgary), M Yeung (Calgary), R Busche (Calgary), R Zabad (Calgary), D Hanley (Calgary)

F-05  Macrophages stimulated by glatiramer acetate produce growth factors for oligodendrogenesis
C Silva* (Calgary), V Skihar (Calgary), W Yong (Calgary)

F-06  EMMPRIN-dependent Early Metalloproteinase Regulation in Murine Experimental Autoimmune Encephalomyelitis (EAE)
SM Agrawal* (Calgary)

F-07  Multiple sclerosis and brain neoplasm: a report of two cases
PG Boulton* (Halifax), R MacAulay (Halifax), S Kirby (Halifax), V Bhan (Halifax)

F-08  Three-year outcome of minocycline treatment in patients with Multiple Sclerosis
Y Zhang* (Calgary), VW Yong (Calgary), RB Bell (Calgary), M Yeung (Calgary), D Patry (Calgary), JR Mitchell (Calgary), LM Metz (Calgary)

EPILEPSY AND EEG

CHAIR: Seyed Mirsattari  

G-01  Temporal and spatial attributes of high frequency oscillations in the pre-ictal period in humans
H Khosravani* (Calgary), N Mehrotra (Calgary), M Rigby (Calgary), W Hader (Calgary), N Pillay (Calgary), S Wiebe (Calgary), P Federico (Calgary)

G-02  Gamma knife treatment for symptomatic epilepsy due to vascular malformations
F Moreau* (Sherbrooke), C Deacon (Sherbrooke), K Brendan (Sherbrooke), M David (Sherbrooke)
G-03  **Self-reported Memory after temporal lobe surgery**  
*SM Baz* (London), R McLachlan (London), S Hayman-Abello (London), P Derry (London), A Alhousawi (London)

G-04  **Reversible widespread leukoencephalopathic changes secondary to uncontrolled partial complex epilepsy**  
*V Ciura* (Calgary), C Toth (Calgary), D McDougall (Calgary)

G-05  **Reorganization of semantic noun processing in left temporal lobe epilepsy**  
*J Edwards* (Calgary), A Bass (Calgary), B Goodyear (Calgary), P Federico (Calgary)

G-06  **Modulation of fusiform face response by emotional facial expression**  
*AO Hebb* (Seattle), KJ Miller (Seattle), H Panagiotides (Seattle), JG Ojemann (Seattle)

G-07  **T2 relaxometry and voxel-based statistics for MR imaging of epilepsy**  
*RK Kosior* (Calgary), ML Lauzon (Calgary), R Frayne (Calgary), P Federico (Calgary)

G-08  **Prevalence of non-convulsive status epilepticus in patients with impaired level of consciousness**  
*RA ALROUGHANI* (Vancouver), M JAVIDAN (Vancouver), N AL-OTAIIBI (Vancouver), A Qasem (Vancouver), H Chou (Vancouver)

G-09  **Anticonvulsant effects on functional MRI signal characteristics**  
*G Mijne* (Calgary), R Samji (Calgary), D Pittman (Calgary), E Jensen (Calgary), J Edwards (Calgary), B Goodyear (Calgary), P Federico (Calgary)

---

**General Neurosurgery II**

**Chair:** RAMESH SAHJPAUL

**Salon 4**

H-02  **Comparison of section of filum terminale and non-neurosurgical management for urinary incontinence in patients with normal conus position.**  
*P Steinbok* (Vancouver), R Kariyattil (Vancouver), A MacNeill (Vancouver)

H-03  **Identification of the source of phosphatidylcholine for axon outgrowth and branching**  
*JM Carter* (Edmonton), RB Campenot (Edmonton), JE Vance (Edmonton), DE Vance (Edmonton)

H-04  **Supraorbital keyhole approach via eyebrow incision for skull base lesions**  
*S Stoika* (Montreal), MW Bojanowski (Montreal)

H-06  **Enhancement of sensorimotor behavioural recovery in parkinsonian rats with a multitarget basal ganglia dopaminergic and GABAergic transplantation strategy**  
*K Mukhida* (Halifax), M Hong (Halifax), M McLeod (Halifax), G Miles (Halifax), N Kobayashi (Halifax), B Baghbaderani (Calgary), A Sen (Calgary), L Behie (Calgary), R Brownstone (Halifax), I Mendez (Halifax)

H-07  **Motor cortex stimulation for neuropathic pain: the British Columbia experience**  
*H Low* (Vancouver), CR Honey (Vancouver)

H-08  **Adjunctive use of a non-ionic surfactant improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson’s disease**  
*M Quinn* (Halifax), K Mukhida (Halifax), D Sadi (Halifax), M Hong (Halifax), I Mendez (Halifax)

H-09  **Neurosurgery patients’ knowledge and feelings about the role of residents in their care: A qualitative case study**  
*E Knifed* (Toronto), J July (Toronto), M Bernstein (Toronto)
NEUROMUSCULAR

**Chair: Kristine Chapman**

**Salon 5&6**

**I-01** The role of microglia in ALS  
L Korngut* (London), L Ang (London), M Strong (London)

**I-02** Adverse effects of intravenous immunoglobulin therapy in patients with neuromuscular diseases are limited and tolerable  
J Nadeau* (Calgary), A Bhibhatbhan (Calgary), D McDougall (Calgary), C Toth (Calgary)

**I-03** Adverse effects of acute and chronic corticosteroid therapy in patients with neuromuscular diseases are common and require greater prophylaxis  
D McDougall* (Calgary), A Bhibhatbhan (Calgary), J Nadeau (Calgary), C Toth (Calgary)

**I-04** Examination of congenital DM1 from the US National Registry for Myotonic Dystrophy  
P Prendergast* (London), S Magalhaes (London), C Campbell (London)

**I-05** A unique GJB1 gene mutation in X-linked hereditary motor sensory neuropathy  
L Billinghurst* (Edmonton), H Kolski (Edmonton)

**I-06** National manpower survey on clinical neurophysiology laboratories in Canada  
K Chan* (Edmonton), S Warren (Edmonton), G Young (London)

**I-07** Dyspnea and the use of non-invasive positive pressure ventilation in ALS  
DC Todd (Hamilton), T Lad* (Hamilton), DW Cockcroft (Saskatoon)

PEDIATRIC EPILEPSY

**Chair: Lionel Carmant**

**Salon 13/14**

**J-01** Selective Amygdalohippocampectomy in children versus adults: experience at the University of Alberta  
A Datta* (Edmonton), D Sinclair (Edmonton), M Wheatley (Edmonton), D Gross (Edmonton), S Ahmed (Edmonton)

**J-02** Is fever associated with both a family history and occurrence of febrile seizures?  
KE Gordon* (Halifax), JM Dooley (Halifax), EP Wood (Halifax), PP Bethune (Charlottetown)

**J-03** Somatic comorbidity in children with epilepsy: a Canadian population health survey  
JF Tellez-Zenteno* (Calgary), A Soofi (Calgary), L Hamiwka (Calgary), S Wiebe (Calgary), E Wirrell (Calgary)

**J-04** Frontal lobe epilepsy surgery in childhood: outcome and critical analysis of reasons for lack of success  
MB Connolly* (Vancouver), L Langill (Vancouver), P Steinbok (Vancouver)

**J-05** Iron Deficiency and Febrile Seizures in Children  
JY Yager* (Edmonton), J Tan (Edmonton), R Rosychuk (Edmonton), D Spady (Edmonton), W Craig (Edmonton),  
DS Hartfield (Edmonton)

**J-06** Clinical and EEG features of cingulate epilepsy in children  
DV Schrader* (Vancouver), L Langille (Vancouver), A Singhal (Vancouver), P Steinbok (Vancouver), M Connolly (Vancouver)

**J-07** Physical activity in children/teens with epilepsy compared with that in their siblings without epilepsy  
JS Wong* (Edmonton), E Wirrell (Calgary)

**J-08** Outcome after Vagal Nerve Stimulation in Children with Intractable Epilepsy  
P Steinbok* (Vancouver), MB Connolly (Vancouver), EM Sherman (Calgary), K Farrell (Vancouver)

CEREBROVASCULAR SURGERY AND INTERVENTIONAL APPROACHES

**Chair: Ian Fleetwood**

**Salon 12**

**K-01** Proposal for development of a Canadian Intracranial Aneurysm (CIA) Registry  
L DaCosta* (Toronto), J Spears (Toronto), B Gray (Toronto), R Macdonald (Toronto), T Marotta (Toronto),  
W Montanera (Toronto), M Tymianski (Toronto), M Wallace (Toronto)

**K-02** Cerebrovascular reactivity changes predict neurological outcome after surgical revascularization for supraclinoid obliterative vasculopathy  
T Kretschmer* (Toronto), DJ Mikulis (Toronto), P Dirks (Toronto), L daCosta (Toronto), M Tymianski (Toronto)
K-03 Multimodality treatment of posterior fossa arteriovenous malformations
ME Kelly* (Cleveland), S John (Ottawa), R Guzman (Stanford), TE Bell-Stephens (Stanford), R Bower (Stanford), S Hamilton (Stanford), MP Marks (Stanford), HM Do (Stanford), GK Steinberg (Stanford)

K-04 Expediting carotid endarterectomy via a rapid access neurovascular clinic
C Harraher* (Halifax), C Dawson (Halifax), I Fleetwood (Halifax), G Gubitz (Halifax), S Phillips (Halifax), G Mackean (Halifax)

K-05 Wait times for carotid endarterectomy for symptomatic patients in community practice
ML Setiawan* (Calgary), MD Hill (Calgary), JH Wong (Calgary)

K-06 Revascularization surgery in moyamoya disease improves clinical disability and reduces the incidence of new TIA or stroke
R Guzman* (Stanford), ME Kelly (Cleveland), T Bell-Stephens (Stanford), GK Steinberg (Stanford)

K-07 Dynamic imaging of a model of saccular intracranial aneurysms using ultra-high resolution flat-panel volume CT
AP Mitha* (Boston), B Reichardt (Boston), CS Ogilvy (Boston), R Gupta (Boston)

K-08 Unruptured cerebral aneurysms presenting with ischemic events
N McLaughlin* (Montreal), MW Bojanowski (Montreal)

K-09 Simvastatin causes endothelin-1-mediated vascular smooth muscle cell relaxation in a cellular-engineered model of cerebral vasospasm
AP Mitha* (Cambridge), ER Balesh (Cambridge), RE Horton (Cambridge), ML McCain (Cambridge), ML O’Grady (Cambridge), K Parker (Cambridge)

SPINE
CHAIR: ERIC MASSICOTTE
SALON 2

L-01 Is age a key determinant of neurological outcome following traumatic spinal cord injury? Analysis of the Second National Acute Spinal Cord Injury Study (NASCIS 2) database
JC Furlan* (Toronto), MG Fehlings (Toronto), MB Bracken (New Haven)

L-02 Motoneuron cell death is not responsible for the impaired nerve regeneration after chronic and sequential nerve injury
R Midha* (Calgary), Q Xu (Calgary), J Forden (Calgary), T Gordon (Edmonton)

L-03 Transient SSEP change can detect iatrogenic spinal cord injury during spine surgery
DA Houlden* (Toronto), M Nolan (Toronto), DW Rowed (Toronto), ML Schwartz (Toronto), M Fazi (Toronto), F Pirouzmand (Toronto), JA Finkelstein (Toronto), A Yee (Toronto)

L-04 Autologous activated macrophage implantation in a large animal model of spinal cord injury: motor recovery without axonal regeneration
R Assina* (Phoenix), C Ma (Phoenix), T Sankar (Phoenix), KM Horn (Phoenix), N Theodore (Phoenix), AR Gibson (Phoenix), MC Preul (Phoenix)

L-05 Reorganization of the primary motor and sensory cortices in patients with spinal cord compression: a pre and postsurgical evaluation using functional MRI

L-06 A prospective study to assess the reliability of a digital imaging-based assessment for cord compression and canal compromise after traumatic cervical spinal cord injury
JC Furlan* (Toronto), MG Fehlings (Toronto), EM Massicotte (Toronto), B Aarabi (Baltimore), A Vaccaro (Philadelphia), CM Bono (Boston), I Madrazo (Mexico City), C Villanueva (Barcelona), J Grauer (New Haven), D Mikulis (Toronto)

L-07 Kyphoplasty - expanding indications
R Sahjipaul* (Vancouver), S Gul (North Vancouver), J Padilla (North Vancouver), J Clement (Vancouver)

L-08 Posterolateral or transverse lumbar interbody fusion (PLIF or TLIF) procedure for degenerative lumbosacral disease via a minimally invasive approach: a retrospective comparative study
N Marcotte* (Quebec City), M Lacroix* (Quebec City)

L-09 Fusion protein of soluble TNF receptor II and a thermally responsive peptide for sustained drug delivery
MF Shanjii* (Ottawa), AH Friedman (Durham), WJ Richardson (Durham), A Chilkoti (Durham), LA Setton (Durham)
NEURO-Oncology

**Chair:** Ian Parney

**Salon 3**

**M-01**
Purely endoscopic transethmoidal transphenoidal surgical approach for non-secreting macro-adenomas with suprasellar extension

N McLaughlin* (Montreal), F Lavigne (Montreal), C Beauregard (Montreal), MW Bojanowski (Montreal)

**M-02**
Practice audit: prophylactic peri-operative antiepileptic drug administration in patients with newly diagnosed malignant gliomas

SH Luw* (Calgary), PA Forsyth (Calgary), JG Cairncross (Calgary), IF Parney (Calgary)

**M-03**
A combined epigenetic and genetic genome-wide screen identifies SPINT2 as a novel tumour suppressor gene in medulloblastoma

PN Kongkham* (Toronto), P Northcott (Toronto), Y Nakahara (Toronto), MD Taylor (Toronto), JT Rutka (Toronto)

**M-04**
Immunotherapy with a synthetic peptide improves response to radiotherapy in a murine glioma model

T Sankar* (Phoenix), R Assina (Phoenix), C Ma (Phoenix), LL Eggink (Tempe), J Hooper (Tempe), SW Coons (Phoenix), AC Scheck (Phoenix), MC Preul (Phoenix)

**M-05**
Complications associated with frame-based stereotactic diagnostic brain biopsy: a 622 case single-surgeon series

PN Kongkham* (Toronto), E Knifed (Toronto), M Bernstein (Toronto)

**M-06**
Identification of a mutation of the transmembrane/cytoplasmic domain of the cation independant mannose 6-phosphate receptor (CI-M6PR) in gliomas. An evaluation of receptor expression and function

RG Kerr* (Edmonton), B Motyka (Edmonton), M Farr-Jones (Edmonton), H Chen (Edmonton), CR Bleackley (Edmonton), KC Petruk (Edmonton)

**M-07**
Screening for CNS tumour therapy sensitivity using an ex vivo invasion assay


**M-08**
Normal human monocytes cultured with glioma cells resemble myeloid suppressor cells

IF Parney* (Calgary), JC Rodrigues (Calgary), G Gonzalez (Calgary), L Zhang (Calgary), G Ibrahim (Calgary), JJ Kelly (Calgary), PA Forsyth (Calgary), VW Yong (Calgary)

**M-09**
Purely endoscopic transethmoidal transphenoidal approach for Cushing’s disease

MW Bojanowski* (Montreal), N McLaughlin (Montreal), C Beauregard (Montreal), F Lavigne (Montreal)

**M-10**
Recurrent low grade gliomas: prognosis and volumetric analysis of resection

AO Hebb* (Seattle), DL Silberberg (Seattle), RC Rostomily (Seattle)

CRITICAL CARE

**Chair:** Jeanne Teitelbaum

**Salon 15/16**

**N-01**
EEG for Prognosis after cardiac arrest

EA AL Thenayan* (London), M Savard (Quebec), M Sharpe (London), L Norton (Ste-Catharines), GB Young (London)

**N-02**
Functional MRI and EEG in the comatose survivor of cardiac arrest


**N-03**
Effect of hyperthermia on outcome in patients with aneurismal subarachnoid hemorrhage

BW Lo* (Mississauga), D Jichici (Hamilton), L Thabane (Hamilton), L Gould (Hamilton), E Klourfeld (Hamilton)

**N-04**
Factors influencing neurologic outcome in aneurysmal subarachnoid hemorrhage patients

BW Lo* (Hamilton), D Jichici (Hamilton), L Thabane (Hamilton)

**N-05**
The frequency and clinical impact of hyperglycemia after acute spinal cord injury: a controlled cohort study with molecular examination of human spinal cord tissue

JC Furlan* (Toronto), MG Fehlings (Toronto)

**N-06**
Continuous EEG-monitoring for sedation management in severe GBS - a report of two cases

M Savard* (Quebec), EA AL Thenayan (London), MD Sharpe (London), L Norton (Ste-Catharines), GB Young (London)
PLATEFORM / POSTER PRESENTATIONS

N-07  Detection of seizures in ICU by a 4-channel bedside system compared to standard EEG
M Savard* (Quebec), EA AL Thenayan (London), MD Sharpe (London), L Norton (Ste-Catharines), GB Young (London)

N-08  The validity of predictors of poor neurological outcome following therapeutic hypothermia for cardiac arrest
EA AL Thenayan* (London), M Savard (Quebec), L Norton (Ste-Catharines), M Sharpe (London), GB Young (London)

POSTER PRESENTATIONS

ALL POSTER PRESENTATIONS ARE LOCATED IN THE EXHIBIT HALL
(SEE DAILY EVENTS CALENDAR FOR TIMES)

CEREBROVASCULAR SURGERY AND INTERVENTIONAL APPROACHES

P-001  The effects of stenting and endothelial denudation on aneurysm and branch occlusion in experimental aneurysm models
TE Darsaut* (Edmonton), I Salazkin (Montreal), S Lerouge (Montreal), G Gervy (Montreal), G Soulez (Montreal), G Gevry (Montreal),
F Bouzeghrane (Montreal), J Raymond (Montreal)

P-002  Monitoring of intracranial aneurysms treated with “Neuroform” stent-assisted coiling using contrast-enhanced MR angiography
F al-Azri (Ottawa), M Santos (Ottawa), H Lesiuk (Ottawa), W Miller (Ottawa), M Goyal (Calgary), C Lum* (Ottawa)

P-003  Symptomatic superficial siderosis associated with an intracranial arteriovenous malformation
N McLaughlin* (Montreal), MW Bojanowski (Montreal)

P-004  Ruptured cerebral aneurysm revealed by the presence of severe vasospasm
N McLaughlin* (Montreal), MW Bojanowski (Montreal)

P-005  Atherosclerotic occlusive disease influences prognosis of patients with aneurysmal subarachnoid hemorrhage
N McLaughlin* (Montreal), MW Bojanowski (Montreal)

P-006  Proximal anterior cerebral artery occlusion for the treatment of large and giant fusiform aneurysms: is bypass required?
M Labib* (London), SJ Peerless (Florida), CG Drake (London), S Lownie (London)

P-007  Stent reconstruction of wide necked aneurysms across the circle of Willis
ME Kelly* (Cleveland), R Turner, IV (Cleveland), V Gonugunta (Cleveland), HH Woo (Cleveland), PA Rasmussen (Cleveland),
TJ Masaryk (Cleveland), D Fiorella (Cleveland)

P-008  Assessment of brain aneurysms after endovascular coiling using high-resolution magnetic resonance angiography
JH Wong* (Calgary), AP Mitha (Calgary), M Wilson (Calgary), ME Hudon (Calgary), R Sevick (Calgary), R Frayne (Calgary)

P-009  Hydrocephalus after coiling of a large unruptured intracranial aneurysm
N Chaudhary* (Brampton), D Sarma (Hamilton), T Gunnarsson (Toronto), N Murty (Hamilton), P Klurfan (Hamilton)

P-010  Skin necrosis after Onyx embolization of a scalp AVM
N Chaudhary* (Brampton), D Sarma (Hamilton), T Gunnarsson (Toronto), K Reddy (Hamilton), P Klurfan (Hamilton)

P-011  Case cost analysis for patients undergoing surgical clipping and endovascular coiling of intracranial aneurysms at St. Michael's Hospital, University of Toronto
L DaCosta* (Toronto), J Spears (Toronto), B Gray (Toronto), T Marotta (Toronto), W Montanera (Toronto)

P-012  Efficiency and security of endovascular treatment for symptomatic carotid stenosis
D Mercier* (Quebec City), G Milot (Quebec City), J Gariepy (Quebec City), J Mercier (Quebec City)

DEMENTIA

P-013  Do haplogroups H and U act to increase the penetrance of Alzheimer’s disease?
M Shafa Shariat Panahi* (Tehran), M Houshmand (Tehran), F Fesahat (Tehran), K Charagozli (Tehran)

P-014  Efficacy of galantamine in patients with rapidly progressing Alzheimer’s Disease
F Dunbar* (Toronto), S Gauthier (Montreal), F Camacho (Toronto)

P-015  Two cases of sporadic Creutzfeldt Jacob disease, one with and the other without dementia at onset
BA van AdeI* (Hamilton), A McDougall (Hamilton), M Puglia (Hamilton), T Xeno (Hamilton), N Nutiu (Hamilton),
C Costiniuk (Hamilton), B Lo (Hamilton), R Lo (Hamilton), JP Provias (Hamilton)
**EPILEPSY AND EEG**

P-016  Somatic comorbidity in adolescents and adults with epilepsy in the general population  
A Ausaaf Soofi (Calgary), JF Tellez-Zenteno* (Calgary), S Wiebe (Calgary)

P-017  The EEG correlates of cerebellar fits  
Y Nadeau* (Quebec), R Desbiens (Quebec)

P-018  Simultaneous intracranial EEG-fMRI at 3 Tesla: A phantom safety study using subdural electrodes in a high-field MR environment  
SM Boucousis (Calgary), CJ Cunningham (Calgary), BG Goodyear (Calgary), P Federico* (Calgary)

P-019  Safety and feasibility of using implanted depth electrodes for intracranial EEG-fMRI: a phantom study  
SM Boucousis (Calgary), CJ Cunningham (Calgary), BG Goodyear (Calgary), P Federico* (Calgary)

**GENERAL NEUROLOGY**

P-020  Epilepsy surgery in patients above 50 years of age - preliminary meta-analysis findings  
J McDermott* (St Laurent), S Wiebe (Calgary)

P-021  Magnetoencephalography: A systematic review of its use in localization-related epilepsy  
M Lau* (London), D Yam (London), JG Burneo (London)

P-022  Sequential motor phenomena of secondarily generalized seizures  
SM Baz* (London), WT Blume (London)

P-023  Metastatic testicular choriocarcinoma presenting as recurrent intracerebral haemorrhage and atypical angiographic appearance  
G Pfeffer* (Vancouver), MK Heran (Vancouver)

P-024  Empty sella in patients with diagnosis of pseudotumor cerebri  
A Asghari Roodsari* (Tehran), A Tabassi (Tehran), A Ghorbani (Tehran), H H.Kharazi (Tehran)

P-025  Bilateral optic nerve head hemangioma in Von Hippel Lindau Disease  
A Abdollahi* (Tehran), Z Hallaji (Tehran), A Mirshahi (Tehran)

P-026  Ross Syndrome-a case series  
H Chua* (Singapore), J Chai (Singapore), K Lim (Singapore), S Lim (Singapore)

P-027  Compulsive gambling induced by Pramexipole in a patient with restless leg syndrome  
B McLane* (Calgary), GM Klein (Calgary)

P-028  Neurological complications of miliary tuberculosis  
A Kar* (Lucknow)

P-030  Effects of vit-C on lead toxicity on rat hippocampus  
I Kermanian* (Tehran)

P-031  Granulomatous angiitis associated with cerebral amyloid angiopathy: A case report with radio-pathological correlation  

P-032  Incidence of migraine in high school students in Khorramabad  
P- Bahrami* (Khorramabad), S- Nadri (Khorramabad), H- Mahmmodvand (Khorramabad)

P-033  Tramadol induced seizure disorder  
P- Bahrami* (Khorramabad), K Mahkami (Khorramabad)

P-034  Longitudinal motor cortex and spinal motor neuron changes in multiple system atrophy  
T Muayqil* (Edmonton), KM Chan (Edmonton), C Hanstock (Edmonton), J Wong (Edmonton), W Johnston (Edmonton), S Kalra (Edmonton)

P-035  Etiology of oculomotor nerve paralysis  
J Chai (Singapore), J Chai (Singapore), A Abdollahi (Tehran), A Tabassi (Tehran)

P-036  CADASIL  
A Malhotra* (Hartford), D Chenouda (Newington)

P-037  Central pontine myelinolysis masquerading as a sensory neuronopathy  

P-038  Gray matter atrophy In primary lateral sclerosis  
P-039 Gordon Holmes Syndrome: A case of hypogonadotropic hypogonadism and cerebellar ataxia  
FC Lam* (Edmonton), MK Heran (Vancouver)

P-040 HIV presenting as myelopathy and bilateral optic neuropathy  
J Lee* (Vancouver), G Pfeffer* (Vancouver)

P-041 Leukoencephalopathy with calcifications and cysts: a case report  
RK Zabad* (Calgary), J Scott (Calgary), LM Metz (Calgary)

P-042 Apoplectic resolution of a pituitary macroadenoma following cardiac surgery  
K Mukhida* (Toronto), G Kolyvas (Saint John)

P-043 Dermal sinus tract and intradural dermoid cyst presenting in late adulthood: a case report and literature review  
A Raut* (Hamilton), A Fallah* (Hamilton), K Reddy* (Hamilton)

P-044 Nodular Fasciitis presenting simultaneously in the obturator nerve and gracilis muscle: Case Report  
A Fallah* (Hamilton), J Lu (Calgary), J Crochmal* (Calgary), L DiFrancesco (Calgary), M Khalil (Calgary), AW Clark (Calgary), R Midha (Calgary)

P-045 An alternative service delivery model for infants with positional plagiocephaly  
P Mortenson (Vancouver), J Rippon* (Vancouver), P Steinbok (Vancouver)

P-046 Early versus delayed cell transplantation in the partial lesion Parkinsonian rodent model  
TJ Phillips* (Halifax), D Sadi (Halifax), M Hong (Halifax), I Mendez (Halifax)

P-047 Chiari 1 and hydrocephalus: another treatment alternative  
G Lapointe* (Québec), A Turmel (Québec)

P-048 The role of bFGF-2 in the retrograde repression of axonal regeneration after injury in the central nervous system  
AS Wu* (Saskatoon), DR Fourney (Saskatoon), D Schreyer (Saskatoon)

P-049 Spontaneous regression of cervical facet synovial cysts - a case report and review of literature  
B W Lo* (Hamilton), S Banglawala (Hamilton), K Reddy (Hamilton)

P-050 Case of Chiari Type I Malformation in an infant with Type 2 Pfeiffer Syndrome and Cloverleaf Skull Deformity: further evidence for an acquired pathogenesis  
A Al-Hayek* (London), D Matic (London), A Ranger (London)

P-051 Decompressive hemicraniectomy in large putaminal haematoma: an Indian experience  
R Ramachandran* (Trivandrum), D Anto (Trivandrum), A T.V. (Trivandrum), S Muthuvel (Trivandrum), R Nayar (Trivandrum)

P-052 Nodular Fasciitis presenting simultaneously in the obturator nerve and gracilis muscle: case report  
JK Crochmal* (Calgary), A Fallah (Hamilton), J Lu (Calgary), L DiFrancesco (Calgary), AW Clark (Calgary), R Midha (Calgary)

P-053 Endoscopic repair of craniosynostosis  
V Mehta* (Edmonton), W Beaudoin (Edmonton), L Peterson (Edmonton), K Aronyk (Edmonton)

P-054 Rupture of arachnoid cysts in children: a report of 2 cases  
G Murray* (St. John’s), FB Maroun (St. John’s), J Jacob (St. John’s), R Avery (St. John’s), M Alam (St. John’s), S Bridger (St. John’s), B Cramer (St. John’s)

P-055 Central neurocytoma: A tumour in evolution  
FB Maroun (St. John’s), R Avery (St. John’s), J Barron (St. John’s), A Norman (St. John’s), G Murray (St. John’s), A Engelbrecht (St. John’s), N Hache (St. John’s)

P-056 Intracranial rhabdomyosarcoma metastasis: A case report  
G Murray* (St. John’s), FB Maroun (St. John’s), R Avery* (St. John’s), A Engelbrecht (St. John’s), J Barron (St. John’s)

P-057 Intraoperative MRI verification of extent of resection in corpus callosotomy  
P Dhaliwal* (Calgary), N Pillay (Calgary), L Hamiwnka (Calgary), S Wiebe (Calgary), W Hader (Calgary)

P-058 Ischemic white matter injury in kaolin-induced neonatal rat hydrocephalus  
OH Khan* (Winnipeg), MR Del Bigio (Winnipeg)

P-059 Idiopathic orbital hemorrhage of extraocular muscle: case report and review of literature  
M Larroche* (Montreal), N McLaughlin (Montreal), MW Bojanowski (Montreal)
POSTER PRESENTATIONS

P-060 Klippel Feil syndrome associated with a craniocervical dermoid cyst
N McLaughlin* (Montreal), J Demers (Montreal), D Shedid (Montreal)

P-061 Sensorimotor behaviours are not adversely affected by chronic amphetamine administration in the rat model of Parkinson’s disease
S Massoud* (Halifax), D Sadi (Halifax), M Hong (Halifax), I Mendez (Halifax)

P-062 Angiographically-negative venous congestive myelopathy - case report
R Sahjpaul* (Vancouver), B Toyota (Vancouver)

P-115 Chiari-syringomyelia complex and posterior fossa decompression : relationship between radiological and clinical improvement. A consecutive series of 34 cases.
HT Khuong* (Quebec), A Turmel (Quebec)

MOVEMENT DISORDERS

P-063 The protective effect of quercetin in an experimental model of Parkinson disease : a behavioral and histochemical analysis in adult rat
M Joghataei* (Tehran), M Mehdizadeh (Tehran), R Aryanpour (Tehran), M Roghani (Tehran), M Nobakht (Tehran)

MUSCULAR SCLEROSIS

P-064 In pictures: multiple sclerosis - a neuroradiological review of its features and differential diagnoses
S Chakraborty* (Ottawa), T Nguyen (Ottawa), M Santos (Ottawa), M Kingstone (Ottawa), C Lum (Ottawa), W Miller (Ottawa)

P-065 Bilateral horizontal gaze palsy and severe trismus in multiple sclerosis: A case report
S Michaud* (Longueuil), L Berger (Longueuil), Z Nasreddine (Longueuil), J Boulanger (Longueuil)

P-066 Skin changes in patients with relapsing-remitting multiple sclerosis on immunomodulatory therapy
RK Zabad* (Calgary), D Lavorato (Calgary), DG Patry (Calgary), C Harris (Calgary), K Billesberger (Calgary), S Peters (Calgary), L Tillotson (Calgary), K Hogue (Calgary), W Wall (Calgary), LM Metz (Calgary)

N EUROMUSCULAR

P-069 Maximizing swallowing ability in ALS through increased sensory input: A case study
S Cleary* (Edmonton), S Krawczyk (Edmonton), S Kizar (Edmonton), S Kalra (Edmonton), W Johnston (Edmonton)

P-070 Juvenile seronegative generalized myasthenia gravis- an atypical presentation
A Datta* (Edmonton), H Kolski (Edmonton)

P-071 A supratentorial primitive neuroectodermal tumor (PNET) in an adult male
PG Boulton* (Halifax), AS Easton (Halifax), DB Clarke (Halifax)

P-072 Recurrent intracranial germ cell tumor with diffuse white matter and optic nerve involvement
H Block* (Edmonton), B Wheatley (Edmonton), E Johnson (Edmonton), G Blevins (Edmonton)

P-073 Defective dendritic cell maturation in malignant glioma patients
IF Parney* (Calgary), J Rodrigues (Calgary), L Zhang (Calgary), G Gonzalez (Calgary)

P-074 Gliomatosis cerebri: a case report
L Ogieglo* (Saskatoon), K Meguro (Saskatoon), S Hentschel (Saskatoon)

P-075 Intracranial subependymomas: clinico-pathological characteristics
M Laroche* (Montreal), F Berthelet (Montreal), MW Bojanowski (Montreal)

P-076 Supratentorial Extra-Axial Ependymoma: Case Report
NR Awan* (Riyadh), KN Al-Musrea (Riyadh)
**PEDIATRIC**

**P-077** Multiple short segment laminoplasties in children: a novel technique to avoid postoperative spinal deformity  
*P Steinbok* (Vancouver)

**P-078** Long-term outcome of infants with positional occipital plagiocephaly  
*P Steinbok* (Vancouver), D Lam (Vancouver), S Singh (Vancouver), P Mortenson (Vancouver), A Singhal (Vancouver)

**P-079** Posterior reversible encephalopathy syndrome in the pediatric population: the Montreal Children's Hospital experience  
*MG Ziller* (Sherbrooke), B Rosenblatt (Montreal), C Poulin* (Montreal)

**P-080** Acute and long term neurological complications of bacterial meningitis in children  
*NJ Lowry* (Saskatoon), ML Garner (Saskatoon)

**P-081** Adherence of children to MS disease modifying therapy  
*JK Mah* (Calgary), LM Metz (Calgary), B Buckner (Calgary), J Bakker (Calgary), W Wall (Calgary), C Harris (Calgary)

**P-082** Adherence in children and adolescents with recurrent headache (RH) and chronic daily headache (CDH)  
*DF Phillips* (Saskatoon), SS Seshia (Saskatoon), CL von Baeyer (Saskatoon)

**P-083** Occipital bone compression of the superior sagittal sinus as a contributory factor in neonatal cerebral sinovenous thrombosis  
*MA Tan* (Toronto), M Shroff (Toronto), M Moharir (Toronto), A Pontigon (Toronto), G deVeber (Toronto), A Kirton (Toronto)

**P-084** A pediatric neurology elective in the far north: a pilot experience  
*A Doja* (Ottawa), H McMillan (Ottawa), P Jacob (Ottawa)

**P-085** Congenital myotonic dystrophy: An update of the Canadian incidence and cohort study  
*C Campbell* (London), SL Venance (London), P Jacob (Ottawa), V Siu (London)

**SPLINE**

**P-086** Hemilaminectomy employment in removal of spinal cord tumors  
*Wm Sbeiti* (Riad), A Zaki (Riad)

**P-087** Effects of degenerative disc disease on the cervical disc height  
*D Rabin* (London), N Duggal (London), R Bertagnoli (Straubing), ML Fink (London)

**P-088** Anatomical differentiation between lamina of fourth and fifth lumbar vertebrae: diagnostic and clinical perspectives in lumbar spine surgeries  
*M Shimia* (Tabriz), P Vahedi* (Tabriz), I Lotfinia (Tabriz), A Karimpour (Tabriz)

**P-089** Bilateral transnasal endoscopic approach to the odontoid  
*BW Lo* (Hamilton), A Lee (Hamilton), D Sommer (Hamilton), N Murty (Hamilton)

**P-090** Distal spinal cord infarction simulating intramedullary tumour - a case report  
*BW Lo* (Hamilton), B Van Adel (Hamilton), K Reddy (Hamilton)

**P-091** Traumatic retroclival hematoma: an uncommon pediatric injury  
*K Aal Ali* (Halifax), P McNeely (Halifax), W Howes (Halifax), S Walling (Halifax)

**P-092** Unusual presentation of intramedullary post-traumatic syrinx  
*G Murray* (St. John’s), FB Maroun (St. John’s), R Avery (St. John’s), A Engelbrecht (St. John’s), M Stefanelli (St. John’s), P Bartlett (St. John’s), N Hache (St. John’s), R Heale (St. John’s)

**P-093** Intracranial hypotension due to Tarlov’s cyst  
*G Murray* (St. John’s), FB Maroun (St. John’s), C Go (St. John’s), A Engelbrecht (St. John’s), R Avery (St. John’s), P Bartlett (St. John’s)

**P-094** Biomechanical evaluation of the Prestige™ cervical intervertebral disc prosthesis  
*D Rabin* (London), N Duggal (London), AG Brantley (Phoenix), S Baek (Phoenix), NR Crawford (Phoenix)

**P-095** Percutaneous placement of C1-2 trans-articular screws  
*M Nikolaïs* (Edmonton)

**P-096** In vivo kinematic results after ProDisc-C total disc replacement  
*D Rabin* (London), R Bertagnoli (Straubing), N Wharton (Houston), GE Pickett (London), N Duggal* (London)

**P-097** Grisel syndrome in adult patients. report of two cases and a review of the literature  
*Y Karam* (Montreal), G Boubez (Montreal), D Shedid (Montreal)

**P-098** Case report: intramedullary neurosarcoidosis  
*S Gul* (North Vancouver), R Sahjpaul (Vancouver)

**P-099** Case report: minimally invasive spinal instrumented fusion for trauma  
*S Gul* (North Vancouver), R Sahjpaul (Vancouver)
**STROKE**

P-100 Excellent treatment response in basilar thrombosis despite prolonged unconsciousness and brainstem radiological changes  
MS Hussain* (Edmonton), T Yeo (Edmonton), MW Hussain (Edmonton), MA Hussain (Edmonton), K Butcher (Edmonton)

P-102 Effect of combined hypothermia and creatine on perinatal hypoxic-ischemic brain damage  
SL Hess* (Edmonton), KG Todd (Edmonton), EA Armstrong (Edmonton), A Terekhov (Edmonton), JY Yager (Edmonton)

P-103 Unilateral critical carotid stenosis with bilateral manifestation: the shaking limbs TIA  
M Abdul* (Edmonton), MM Siddiqui (Edmonton), K Khan (Edmonton), A Shuaib (Edmonton)

P-105 A cool handed right hemispheric stroke  
G Jickling* (Edmonton), M Mouradian (Edmonton), J Scozzafava (Edmonton), A Shuaib (Edmonton)

P-106 How well is hyperlipidemia managed after ischemic stroke?  
D Manawadu* (Edmonton), AM Nasser (Edmonton), A Mateer (Edmonton), A Shuaib (Edmonton)

P-107 Treatment of acute ischemic stroke affected by time-related factors  
H Hamid* (Edmonton), AM Nasser (Edmonton), MS Hussain (Edmonton), M Hamadeh (Edmonton), M Siddiqui (Edmonton),  
A Salam (Edmonton), M Saqqur (Edmonton), A Shuaib (Edmonton), K Khan (Edmonton)

P-108 Emergency Medical Services (EMS) has an important role in tPA administration rate and acute stroke management  
AM Nasser* (Edmonton), A Salam (Edmonton), H Hamid (Edmonton), M Hamadeh (Edmonton), M Saqqur (Edmonton),  
A Shuaib (Edmonton), KA Khan (Edmonton), M Siddiqui (Edmonton)

P-109 Caregiver burden following stroke: Identifying caregivers at risk  
H Rigby* (Halifax), G Gubitz (Halifax), S Phillips (Halifax)

P-110 The prevalence of carotid intima media thickness in TIA or Stroke patients with and without metabolic syndrome  
P Maheshwari* (Edmonton), M Ibrahim (Edmonton), S Hussain (Edmonton), C Derksen (Edmonton), M Siddiqui (Edmonton),  
A Mateer (Edmonton), H Haroon (Edmonton), D Manawadu (Edmonton), A Shuaib (Edmonton)

P-111 Stroke outcome scale  
NH Rizvi* (Edmonton), M Saqqur (Edmonton), A Shuaib (Edmonton)

P-112 Real-time dynamic assessment of cerebral hemodynamics in a patient with orthostatic aphasia: a potential application of transcranial doppler  
NH Rizvi* (Edmonton), Y Alladin (Edmonton), M Saqqur (Edmonton), S Hussain (Edmonton)

**TRAUMA, CRITICAL CARE**

P-113 Management of severe traumatic brain injury in Saskatchewan  
PA Mercier* (Saskatoon), J Witt (Saskatoon), K Meguro (Saskatoon)

P-114 Effect of troponin rise on outcome in patients with aneurismal subarachnoid hemorrhage  
BW Lo* (Hamilton), D Jichici (Hamilton), L Thabane (Hamilton)
Bayer Inc. #1

Bayer Inc. is a Canadian subsidiary of Bayer AG, an international research-based group with core businesses in health care, crop science, and innovative materials. The Specialized Therapeutics unit of Bayer Inc. is focused on improving the lives of patients living with Multiple Sclerosis (MS) by providing innovative and effective therapies.

Biogen Idec #20

Biogen Idec (NASDAQ: BIIB) creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For press releases and additional information about the company, please visit www.biogenidec.com.

Boehringer Ingelheim Canada Ltd. #31

Boehringer Ingelheim Canada Ltd. (BICL) is a member of the Boehringer Ingelheim group of companies with international headquarters in Ingelheim, Germany. Boehringer Ingelheim is the largest 100% family-owned pharmaceutical company and ranks among the top 20 pharmaceutical companies in the world.

BICL has earned a well-deserved reputation for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and has expanded its product portfolio to include treatments for diseases that affect the Central Nervous System, the Cardiovascular system, and other human conditions. We invite you to visit our website www.boehringer-ingelheim.ca for more information on our company and products.

Bristol-Myers Squibb Canada #8

Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Canada is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS), nervous system diseases and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol. Bristol-Myers Squibb Canada’s operations are headquartered in Montréal, Québec.

Canada Microsurgical Ltd. #12

Canada Microsurgical has been a distributor of neurosurgical products for the past 24 years. We are located in Burlington, Ontario and have representation with a DIRECT SALES FORCE throughout all of Canada.

Carl Zeiss Canada #24

Carl Zeiss offers a complete range of visualization products, ranging from magnifying loupes to neurosurgical microscopes and accessories to meet every need and budget. We are proud to showcase the Opmi Pentero, featuring state-of-the-art optics, integrated video and digital documentation for optimum user ease and operating room workflow. Also on hand is the MediLive MindStream, a complete video documentation system geared to the demanding environment of today’s busy operating room. Please visit the Carl Zeiss booth for a hands-on experience and personal consultation with one of our product experts.

Codman / Johnson & Johnson #3


DePuy Spine is a leading designer and manufacturer of technologies for the treatment of cervical, thoracic, lumbar and sacral pathologies.

In Canada, Codman and DePuy Spine are units of Johnson & Johnson Medical Products, a division of Johnson & Johnson Inc., and are headquartered in Markham, Ontario.
Hoffman LaRoche

Roche is a leader in the research and development of pharmaceutical and diagnostic solutions that look beyond today's horizons and make a profound difference in people’s lives. Working in partnership with healthcare practitioners from across the country, Roche has opened the door to countless new possibilities in the discovery, treatment and management of acute and long term disease. The company is active in a broad range of therapeutic categories including virology, oncology, transplantation and urgent care. The Urgent Care Business Unit is comprised of a dedicated team of individuals managing products for treatment of acute myocardial infarction, stroke and influenza.

Janssen-Ortho Inc.

Janssen-Ortho Inc. is a brand-name pharmaceutical company headquartered in Toronto with a broad range of medications used in psychiatry, neurology, dementia, attention deficit hyperactivity disorder, pain management, women’s health, infectious disease, gastroenterology, and urology.

Leica Microsystems

Leica Microsystems is a leading global innovator, manufacturer and supplier of high precision surgical microscopes.

Medtronic of Canada Ltd.

Medtronic is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

We are proud to be associated with the CNSF to highlight our products and services assisting healthcare professionals in the treatment of pain and neurological, urologic, and spinal disorders.

Merck Frosst Canada Ltd.

Merck Frosst Canada Ltd. is pleased to participate in the 2007 Congress of Canadian Neurological Sciences Federation.

Merck Frosst Canada Ltd. is committed to the field of neurology with a strong focus on facilitating effective management of patients suffering from migraine. For the latest information and related educational resources, please visit the Merck Frosst Canada booth.

Novartis Pharmaceuticals Canada Inc.

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Novartis Pharmaceuticals Canada conducts hundreds of clinical trials across the country seeking new treatments including neuroscience, cardiovascular disease and cancer. The company employs approximately 800 people in Canada and its headquarters are located in Dorval, Quebec.

Novo Nordisk Canada Inc.

“Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,000 employees in 79 countries, and markets its products in 179 countries.”

Pfizer Canada Inc.

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world’s leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer Inc invests more than US$7 billion annually in R&D in a wide range of therapeutic areas, including arthritis, cardiovascular disease, endocrinology, HIV/AIDS, infectious disease, neurological disease, oncology, ophthalmology and smoking cessation. For more information, visit www.pfizer.ca.
**Prestwick Pharmaceuticals Canada**

Prestwick Pharmaceuticals Canada Inc. is a late-stage product-based biopharmaceutical company engaged in the development and marketing of drugs for chronic diseases for diseases of the central nervous system (CNS). Our portfolio of drugs addresses significant unmet medical needs in CNS disorders such as Huntington’s disease, Parkinson’s disease, and schizophrenia.

**Procter & Gamble**

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands. The P&G community consists of almost 140,000 employees working in over 80 countries worldwide. P&G is the leading consumer products company in Canada with over $2.7 billion in annual sales. Please visit www.pgcanada.ca for the latest news and in-depth information about P&G and its brands. P&G Pharmaceuticals is a division of P&G Health.

**Roxon Medi-Tech Ltd.**

Roxon Medi-Tech Ltd. cordially invites you to visit our booth where our knowledgeable staff will present to you the latest neurology equipment - EEG, Ambulatory EEG, EMG, IOM & Sleep.

**Sanofi-aventis Canada Inc.**

Sanofi-aventis Canada Inc. is an affiliate of the Paris-based sanofi-aventis Group, one of the world’s leading pharmaceutical companies. The global company is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. With annual R&D investments of more than four billion euros, the sanofi-aventis Group is moving more than 120 products through its research pipeline in its bid to deliver products that not only improve patients’ quality of life, but can also help lower the overall cost of healthcare.

In Canada, the company’s core products include medications used in the treatment of hypertension, unstable angina, deep vein thrombosis, cancer, post-menopausal osteoporosis and diabetes, and in the prevention of atherothrombotic events such as heart attacks and strokes.

One of the 500 leading companies in Canada, the Canadian operation employs 1,140 people across the country and operates a state-of-the-art manufacturing facility at its corporate headquarters in Laval, Quebec.

**Talecris Biotherapeutics**

Talecris Biotherapeutics is a new company proud to inherit a legacy of more than 60 years of providing lifesaving and life-enhancing plasma-derived therapeutic proteins. Through the assets of Bayer Biological Products’ plasma business, Talecris’ heritage of patient care innovations in therapeutic proteins dates back to the blood-derived products Cutter Laboratories began to produce in the early 1940s. Cutter and its successor companies, including Miles Laboratories and Bayer, were recognized in the industry as producers of innovative products, starting with the development of albumin and continuing with other products for immune deficiencies, genetic lung disease, hemophilia, and passive immunity.

Talecris, having inherited this solid foundation of unparalleled expertise and experience, is now uniquely positioned to create a new standard of excellence in the field of biotherapeutics.

The Talecris New Trials Support (Talents) Program is a novel initiative from Talecris Biotherapeutics that has been designed to support investigator-initiated trials conceived by researchers and clinicians with an interest in using intravenous immune globulin (IGIV) in areas such as immunology, hematology and neurology. Every year the Talents program will provide $1 million to fund basic science and clinical research in these fields.

The international headquarters of Talecris Biotherapeutics are located in Research Triangle Park, North Carolina. Talecris has other offices located in Mississauga - Ontario (Canadian Headquarters), Ottawa - Ontario and Frankfurt, Germany (European Headquarters). Talecris production facilities are located in Clayton, North Carolina and at Precision Pharma Services (a wholly-owned subsidiary) located in Melville, New York.

**Teva Neuroscience**

Teva Neuroscience is a company dedicated to improving the lives of people with neurological diseases. In our comprehensive approach to this complex illness, Teva Neuroscience created Shared Solutions®, a free patient support program that goes beyond the disease and beyond the
treatment to help people living with Multiple Sclerosis enjoy a life as full and rewarding as possible.

Teva Neuroscience’s research and development efforts also encompass ALS, lupus, oncology and epilepsy. Teva Neuroscience is committed to continued innovation in the treatment of neurological and autoimmune disorders, and bringing new options to people living with these devastating diseases.

Valeant Canada Ltd / Valeant Canada limitée

Valeant Canada Limited is a subsidiary of Valeant Pharmaceuticals International, a global pharmaceutical company. Valeant Pharmaceuticals International’s vision is to discover, develop, acquire and commercialise innovative products for the treatment of diseases with significant unmet medical needs primarily in the areas of neurology, dermatology and infectious diseases.

Valeant Canada limitée est une filiale de Valeant Pharmaceuticals International, société pharmaceutique intégrée. La vision de Valeant Pharmaceuticals International est de découvrir, mettre au point, acquérir et commercialiser des produits novateurs servant à traiter des maladies présentant d’importants besoins médicaux non satisfaits, surtout dans les domaines de la neurologie, de la dermatologie et des maladies infectieuses.

XLTEK

XLTEK is an established market leader in the monitoring and diagnosis of conditions affecting the central and peripheral nervous systems. We understand your needs because we listen.

XLTEK is an innovative developer and manufacturer of quality products and services for Electromyography (EMG), Electroencephalography (EEG), Long Term [Epilepsy] Monitoring (LTM), Intra-Operative Monitoring (IOM) and Polysomnography (PSG). We also offer a full portfolio of Neurodiagnostic and Sleep Accessories.

Come see what over 20 years of experience can provide to you: visit us at our booth and visit our website at www.xltek.com to see our full line of solutions. We’re helping you put patient care first!
EMPLACEMENT DU CONGRÈS ET INSCRIPTIONS

Emplacement du congrès
Shaw Conference Centre
9797 Jasper Avenue
Edmonton, Alberta Y5J 1N4

Inscriptions des délégués et des exposants
Bureau des inscriptions
Shaw Conference Centre

Mardi 19 juin 07:30 – 18:30
Mercredi 20 juin 07:00 – 18:30
Jeudi 21 juin 07:00 – 18:30
Vendredi 22 juin 07:00 – 13:30

PROCHAINS CONGRES DE LA FSNC

17 – 20 juin 2008 Victoria, Colombie Britannique
9 – 12 juin 2009 Halifax, Nouvelle Ecosse
8 – 11 juin 2010 Québec, Québec

DES QUESTIONS?

Advance Group
A l’attention de la Fédération des sciences neurologiques du Canada
Suite 101 -1444 Alberni Street
Vancouver, BC, Canada V6G 2Z4
Tel: +1-604-688-9655 (Extension 2)
1-800-555-1099 (Extension 2)
Fax: +1-604-685-3521
E-mail: cnsfinfo@advance-group.com

Details de l’inscription

Inscription complète
• Permet d’assister à toutes les séances du congrès annuel 2007 du mardi 19 juin au vendredi 22 juin.
• Inclut la réception des exposants, la réception du Président le mercredi 20 juin et le dîner du Président du jeudi 21 juin, ainsi que le repas du midi dans la salle d’exposition le jeudi et le vendredi.

Inscription pour une journée
• Ne permet d’assister qu’aux séances scientifiques du mardi, du mercredi, du jeudi et du vendredi.
• N’inclut pas la réception du Président ni le dîner du Président, mais vous pouvez acheter des billets supplémentaires pour ces événements.

Badges
• Les délégués doivent constamment porter leurs badges pour être admis aux cours du Congrès et aux séances scientifiques. Les billets seront collectés pour la réception du Président et le dîner du Président.

Formulaires d’inscription
• Vous pouvez vous inscrire en ligne à www.cnsfederation.org. ou
• Pour poster ou à envoyer par télécopie à:

Advance Group Conference Management
Suite 101 - 1444 Alberni Street
Vancouver, BC, Canada V6G 2Z4
HÉBERGEMENT

Aidez votre Fédération en réservant votre séjour à l’hôtel dans un hôtel partenaire de la FSNC et bénéficiez d’un tarif réduit! Advance Group a été désigné Bureau officiel de l’hébergement pour le 42ème Congrès de la Fédération des sciences neurologiques canadiennes qui se tiendra à Edmonton, AB du 19 au 22 juin 2007. Faites ce qu’il faut pour profiter des tarifs d’hôtel spéciaux réservés aux délégués du Congrès.

Tarifs préférentiels

La FSNC a réservé un bloc de chambres et fixé des tarifs préférentiels pour les délégués de la conférence dans les hôtels suivants:

Fairmont MacDonald
- Simple ou Double $199
- Chambre avec vue $219
- Chambre Deluxe $239
- Deluxe avec vue $259

Pour une 3ème ou 4ème personne, ajoutez $20.00/personne/nuit au type de chambre ci-dessus.

Westin
- Simple ou Double $165

Pour une 3ème ou 4ème personne, ajoutez $25.00/personne/nuit au type de chambre ci-dessus.

Réservation d’hôtel

- Comment faire: Advance Group accepte les demandes d’hôtel en ligne à www.cnsfederation.org ou par télécopie au (604-685-3521) ou par la poste en utilisant un formulaire de réservation d’hôtel de la FSNC. Les réservations par téléphone ne seront pas acceptées.
- Les demandes de renseignements sur les hôtels, les questions, ou toute demande groupée pour 10 chambres ou plus sont à envoyer à l’adresse courrielle suivante: cnsf2007@advance-group.com.
- Les réservations d’hôtel seront attribuées selon les renseignements reçus et dans l’ordre d’arrivée des demandes, selon la disponibilité des hôtels et des chambres.
- Réservations individuelles: pour confirmer chaque réservation de chambre, un acompte de la valeur d’une nuitée est exigé, payable par carte de crédit ou par chèque/mandat à l’ordre de Advance Group. Ce chèque ou mandat (EN DOLLARS CANADIENS) doit accompagner le formulaire de réservation d’hôtel pour que votre réservation soit enregistrée. Veuillez soumettre un formulaire pour chaque chambre réservée.
- Les confirmations d’hôtel vous seront envoyées directement par courriel, par télécopie ou par la poste.
Tous les prix d’hôtel sont en dollars canadiens, par chambre et par nuitée. Il faut ajouter aux tarifs 4% de taxe hôtelière, 6% TPS et 1% taxe tourisme. Les visiteurs résidant hors du Canada peuvent se faire rembourser la TPS sur la portion chambre de leur facture. Vous trouverez des formulaires de remboursement de la TPS à la caisse de l’hôtel.

EVÉNEMENTS SOCAUX

Réception des exposants

Mercredi 20 juin 2007 - 17:30-19:00
Shaw Conference Centre - Niveau congrès-zone d’exposition

Réception du Président

Mercredi 20 juin 2007 - 19:00-21:00
Empire Ballroom, Fairmont MacDonald
Tenue de ville – Rafraîchissements et hors d’œuvres. 2 billets-boisson gratuits puis bar payant. Les tickets d’entrée, qui font partie du forfait pour l’inscription complète, seront émis et collectés à la porte. Des billets extra pourront s’acheter à $30 pièce (plus taxe).

Soirée des résidents

Jeudi 21 juin 2007 - 18:00-19:00
Shaw Conference Centre - Salon 5/6
Tous les résidents sont invités à se mélanger à leurs collègues et aux membres de la FSNC pour faire leur connaissance; Les boissons y seront gratuites.

Dîner du Président

Jeudi 21 juin 2007- 19:00
Shaw Conference Centre - Hall D niveau des passages pour piétons (pedway). Tenue de ville. Dîner à quatre services. Ce dîner fait partie de l’inscription complète, votre badge sera requis pour participer, les billets supplémentaires seront collectés à la porte. Des billets supplémentaires pourront s’acheter à 75$ (plus taxe).
### PROGRAMME DES ACTIVITÉS

#### Lundi 18 juin 2007

<table>
<thead>
<tr>
<th>Heure</th>
<th>Activité</th>
<th>Lieu</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-16:30</td>
<td>FSNC/JSN: réunions du conseil d'administration et de planification</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>16:30-17:30</td>
<td>Réunion du conseil de l’ACNP</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Salle de préparation pour les conférenciers</td>
<td>Salon 7</td>
</tr>
</tbody>
</table>

#### Mardi 19 juin 2007

<table>
<thead>
<tr>
<th>Heure</th>
<th>Activité</th>
<th>Lieu</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-18:30</td>
<td>Inscription</td>
<td>Hall de l’étage Meeting</td>
</tr>
<tr>
<td>07:30-18:00</td>
<td>Salle de préparation pour les conférenciers</td>
<td>Salon 7</td>
</tr>
<tr>
<td>08:00-08:30</td>
<td>Comité de vérification JCSN</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>08:30-09:00</td>
<td>Comité de vérification FSNC</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>08:00-17:00</td>
<td>Cours de révision en neurobiologie</td>
<td>Salon 4</td>
</tr>
<tr>
<td>08:30-17:00</td>
<td>SLA, stratégies pour qualité de vie/ qualité des soins, cours symposium</td>
<td>Salon 3</td>
</tr>
<tr>
<td>08:30-17:00</td>
<td>Jour de neuropédiatrie</td>
<td>Salon 2</td>
</tr>
<tr>
<td>09:00-11:00</td>
<td>Comité de développement professionnel FSNC</td>
<td>Salon 19/20</td>
</tr>
<tr>
<td>10:00-12:00</td>
<td>Comité du programme scientifique FSNC</td>
<td>Salon 19/20</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Déjeuner SLA</td>
<td>Salon 12</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Réunion SCN pour les résidents de neurologie</td>
<td>Wedgewood Fairmont</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Comité EMG, SCNC</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Comité EEG, SCNC</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>12:30-16:30</td>
<td>SCN, éducation et main d’oeuvre, CR comité de spécialité neurologie</td>
<td>Salon 1</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>JCSN, conseil de rédaction</td>
<td>Salon 19/20</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>JCSN comité des publications</td>
<td>Salon 19/20</td>
</tr>
<tr>
<td>13:00-15:00</td>
<td>SLA atelier 2</td>
<td>Salon 15/16</td>
</tr>
<tr>
<td>13:00-15:30</td>
<td>SLA atelier 3</td>
<td>Salon 13/14</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>Réunion du conseil SCNC</td>
<td>Salon 1</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>Réunion du conseil SCNCH</td>
<td>Salon 20</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>Réunion du conseil SCN</td>
<td>Salon 19</td>
</tr>
<tr>
<td>16:30-17:30</td>
<td>Réunion professionnelle, résidents de neurochirurgie</td>
<td>Salon 17</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Assemblée générale annuelle ACNP</td>
<td>Salon 15/16</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Séance vidéo et épilepsie (cours)</td>
<td>Salon 4</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Mouvements anormaux</td>
<td>Wedgewood Fairmont</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>SLA, groupe de pression spécialisé (GPS)</td>
<td>Jasper Room Fairmont</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Neuroroumulaire, GPS</td>
<td>Salon 3</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Réunion pour l’enseignement aux résidents de neurochirurgie</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>18:00-20:00</td>
<td>Enseignement de neurologie aux étudiants</td>
<td>Salon 13 &amp; 14</td>
</tr>
<tr>
<td>18:30</td>
<td>Dîner ACNP - Ruth’s Chris Steak House</td>
<td></td>
</tr>
</tbody>
</table>

#### Mercredi 20 juin 2007

<table>
<thead>
<tr>
<th>Heure</th>
<th>Activité</th>
<th>Lieu</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-18:30</td>
<td>Inscription</td>
<td>Hall de l’étage Meeting</td>
</tr>
<tr>
<td>07:00-18:00</td>
<td>Salle de préparation pour les conférenciers</td>
<td>Salon 7</td>
</tr>
<tr>
<td>07:00-08:00</td>
<td>Neurochirurgie pédiatricienne</td>
<td>Salon 1</td>
</tr>
<tr>
<td>08:00-16:00</td>
<td>Installation des expositions (pour exposants)</td>
<td>Salons 8,9,10 &amp; 11</td>
</tr>
<tr>
<td>08:30-10:30</td>
<td>S. plénière, inauguration - Progrès scientifiques et techniques dans les neurosciences cliniques</td>
<td>Salon 12</td>
</tr>
<tr>
<td>10:45-12:15</td>
<td>Présentation plénière choisie par le président</td>
<td>Salon 12</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Mouvements anormaux, assemblée générale annuelle canadienne</td>
<td>Salon 1</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Groupe canadien neuromusculaire</td>
<td>Salon 17/18</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Réunion CCSCNP (Coalition canadienne pour la santé du cerveau et des nerfs périphériques)</td>
<td>Salon 5</td>
</tr>
<tr>
<td>14:00-17:30</td>
<td>Cours sur la colonne vertébrale</td>
<td>Wedgewood Fairmont</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>EMG Atelier 1</td>
<td>Salon 15</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>EMG Atelier 2</td>
<td>Salon 16</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>EMG Atelier 3</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>EMG Atelier 4</td>
<td>Salon 19</td>
</tr>
<tr>
<td>14:00-17:30</td>
<td>Cours sur les soins d’urgence en neurologie</td>
<td>Salon 3</td>
</tr>
<tr>
<td>14:00-17:30</td>
<td>Cours sur l’épilepsie</td>
<td>Jasper Room Fairmont</td>
</tr>
<tr>
<td>14:00-17:30</td>
<td>Cours sur la douleur neuropathique</td>
<td>Drawing Room Fairmont</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>EMG Atelier 1</td>
<td>Salon 15</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>EMG Atelier 2</td>
<td>Salon 16</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>EMG Atelier 4</td>
<td>Salon 19</td>
</tr>
<tr>
<td>14:00-17:30</td>
<td>Cours sur l’accident vasculaire cérébral</td>
<td>Salon 2</td>
</tr>
<tr>
<td>17:30-19:00</td>
<td>Ouverture de l’exposition (réception des exposants)</td>
<td>Salons 8,9,10 &amp; 11</td>
</tr>
<tr>
<td>19:00-21:00</td>
<td>Réception des Présidents</td>
<td>Salle de bal Empire/Hall/Terrace Fairmont</td>
</tr>
</tbody>
</table>

**Code de couleurs**
- **Assemblée générale annuelle (AGA)**
- **Association canadienne de neurologie pédiatrique (ACNP)**
- **Fédération des sciences neurologiques du Canada (FSNC)**
- **Journal canadien des sciences neurologiques (JCSN)**
- **Société canadienne de neurologie (SCN)**
- **Société canadienne de neurochirurgie (SCNCH)**
- **Société canadienne de neurophysiologie clinique (SCNC)**

Les lettres en bleu désignent des événements du programme scientifique.

Les lettres en noir, des rencontres à caractère commercial ou autre.
## PROGRAMME DES ACTIVITÉS

### Jeudi 21 juin 2007

<table>
<thead>
<tr>
<th>Temps</th>
<th>Activité</th>
<th>Local</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:15</td>
<td>Pour le plaisir, course/marche ACISN pour la recherche neuroscientifique en sciences infirmières. Consultez <a href="http://www.cann.ca">www.cann.ca</a> pour plus de renseignements.</td>
<td></td>
</tr>
<tr>
<td>07:00-18:30</td>
<td>Inscription</td>
<td>Meeting Level Foyer</td>
</tr>
<tr>
<td>07:30-18:00</td>
<td>Salle de préparation pour les conférenciers</td>
<td>Salon 7</td>
</tr>
<tr>
<td>07:30-08:30</td>
<td>Réunion de la Ligue canadienne contre l’épilepsie</td>
<td>Salon 18</td>
</tr>
<tr>
<td>07:30-08:30</td>
<td>Groupe canadien des soins d’urgence en neurologie</td>
<td>Salon 17</td>
</tr>
<tr>
<td>07:30-08:30</td>
<td>Sociétés affiliées à la FSNC</td>
<td>Salon 1</td>
</tr>
<tr>
<td>07:00-08:30</td>
<td>Conseil canadien d’enregistrement des technologistes en EEG (CCETE)</td>
<td>Salon 19</td>
</tr>
<tr>
<td>08:30-10:00</td>
<td>S. plénière – Neurologie SCN, CACN &amp; SCNC</td>
<td>Salon 12</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>S. plénière – Neurochirurgie SCNH</td>
<td>Salon 2</td>
</tr>
<tr>
<td>10:15-12:30</td>
<td>Communications orales libres (Neurochirurgie générale 1)</td>
<td>Salon 4</td>
</tr>
<tr>
<td>10:15-12:30</td>
<td>Communications orales libres (SEP)</td>
<td>Salon 2</td>
</tr>
<tr>
<td>10:15-12:30</td>
<td>Communications orales libres (Neurologie AVG)</td>
<td>Salon 3</td>
</tr>
<tr>
<td>10:15-12:30</td>
<td>Communications orales libres (Neurologie générale)</td>
<td>Salon 12</td>
</tr>
<tr>
<td>10:15-12:30</td>
<td>Communications orales libres (Neuropédiatrie générale)</td>
<td>Salon 5 &amp; 6</td>
</tr>
<tr>
<td>10:15-12:30</td>
<td>Communications orales libres (Epilepsie &amp; EEG)</td>
<td>Salon 13/14</td>
</tr>
<tr>
<td>12:30-14:00</td>
<td>Déjeuner dans la salle des expositions et Communications par affiches et exposition</td>
<td>Salons 8,9,10 &amp; 11</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Communications orales libres (Neurochirurgie générale 2)</td>
<td>Salon 4</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Communications orales libres (Colonne vertébrale)</td>
<td>Salon 2</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Communications orales libres (Neuro-oncologie)</td>
<td>Salon 3</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Communications orales libres (Chirurgie vasculaire cérébrale)</td>
<td>Salon 12</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Communications orales libres (Neuromusculaire)</td>
<td>Salon 5 &amp; 6</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Communications orales libres (Epilepsie de l’enfant)</td>
<td>Salon 13/14</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Communications orales libres (Soins intensifs)</td>
<td>Salon 15/16</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>Groupe canadien de recherche neuromusculaire chez l’enfant</td>
<td>Salon 1</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>Communications affichées électroniques &amp; visite de l’exposition</td>
<td>Salons 8,9,10 &amp; 11</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Réunion de la Fondation de la SCN</td>
<td>Salon 19</td>
</tr>
<tr>
<td>18:00-19:00</td>
<td>Soirée des résidents</td>
<td>Salon 5/6</td>
</tr>
<tr>
<td>19:00</td>
<td>D. des présidents</td>
<td>Hall D</td>
</tr>
</tbody>
</table>

### Vendredi 22 juin 2007

<table>
<thead>
<tr>
<th>Temps</th>
<th>Activité</th>
<th>Local</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-13:30</td>
<td>Inscription</td>
<td>Meeting Level Foyer</td>
</tr>
<tr>
<td>07:30-18:00</td>
<td>Salle de préparation pour les conférenciers</td>
<td>Salon 7</td>
</tr>
<tr>
<td>07:30-08:30</td>
<td>AGA de la Société canadienne des céphalées</td>
<td>Salon 20</td>
</tr>
<tr>
<td>07:00-08:30</td>
<td>AGA de la SCNC</td>
<td>Salon 6</td>
</tr>
<tr>
<td>07:00-08:30</td>
<td>AGA de la Soc. can. de neurochirurgie (SCNCH)</td>
<td>Salon 13/14</td>
</tr>
<tr>
<td>07:00-08:30</td>
<td>AGA de la Soc. can. de neurologie (SCN)</td>
<td>Salon 15/16</td>
</tr>
<tr>
<td>08:30-09:30</td>
<td>Conférence par l’invité de marque</td>
<td>Salon 12</td>
</tr>
<tr>
<td>09:30-09:50</td>
<td>Rapport de la CCSCNP</td>
<td>Salon 12</td>
</tr>
<tr>
<td>09:50-10:00</td>
<td>Présentation du Prix Eminent relecteur de manuscrits et introduction du nouveau rédacteur en chef du JCSN</td>
<td>Salon 12</td>
</tr>
<tr>
<td>09:30-15:00</td>
<td>Tour des communications affichées et des expositions</td>
<td>Salons 8,9,10 &amp; 11</td>
</tr>
<tr>
<td>10:15-12:00</td>
<td>Discussion de cas cliniques</td>
<td>Salon 12</td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>Réunion de la CCSCNP</td>
<td>Salon 17 &amp; 18</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Déjeuner dans la salle d’exposition et tour des communications affichées</td>
<td>Salons 8,9,10 &amp; 11</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Neurochirurgie, comité du Collège royal</td>
<td>Salon 17 &amp;18</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Cours: céphalées</td>
<td>Salon 2</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Cours: quoi de neuf en neurochirurgie</td>
<td>Drawing Room</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Cours: EEG</td>
<td>Salon 4</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Cours: Démence</td>
<td>Salon 3</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Cours: SEP</td>
<td>Salons 5/6</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Cours: Quoi de neuf en neurologie</td>
<td>Wedgewood</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>Cours: neuromusculaire</td>
<td>Salon 12</td>
</tr>
<tr>
<td>14:00-16:30</td>
<td>Réunion du comité des FSNC/CCSN</td>
<td>Salon 17 &amp; 18</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Réunion du Groupe “Canadian Headache Outpatient Registry and Database”</td>
<td>Salon 19</td>
</tr>
</tbody>
</table>

### Samedi 23 juin 2007

<table>
<thead>
<tr>
<th>Temps</th>
<th>Activité</th>
<th>Local</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:30</td>
<td>Assemblée générale annuelle de Pensezd’abord Canada</td>
<td>Salle Winterlake, Hôtel Sutton Place</td>
</tr>
<tr>
<td>09:30-12:30</td>
<td>Réunion des sections de Pensezd’abord Canada</td>
<td>Salle Winterlake, Hôtel Sutton Place</td>
</tr>
</tbody>
</table>
Cours de révision en neurobiologie

Cours généreusement financé par une subvention sans condition à but éducatif de la Fondation de la Société canadienne de neurologie.

Président: Jack Jhamandas

Objectifs du cours: à l’issue de ce cours les participants pourront:
1. Décrire la neurobiologie de la maladie neurodégénérative.
2. Réfléchir à la base neurale du comportement rythmique du SNC.
3. Exposer clairement la neuroimmunologie et la neuroimagerie de la SEP.
4. Faire le point sur les mécanismes et la physiopathologie de l’épilepsie.

Public visé: cliniciens de disciplines connexes de neurosciences (neurologues, neurochirurgiens, neurophysiologistes, etc.) et personnes en cours de formation (résidents, chercheurs, etc.)

MÉCANISMES FONDAMENTAUX DES MALADIES NEURODÉGÉNÉRATIVES
08:00 Neurobiologie de la famille de la protéine prion.................................................................David Westaway, (Edmonton, AB)
08:45 Base moléculaire de la perte de mémoire dans les modèles transgéniques de la maladie d’Alzheimer .................................................................Karen Hsiao Ashe, (Minnesota, USA)
09:30 Discussion
09:45 Pause

BASE NEURALE DU COMPORTEMENT RYTHMIQUE DANS LE SNC
10:00 Contrôle central de la rythmogenèse respiratoire .........................................................John Greer, (Edmonton, AB)
10:45 Progrès récents dans la neurobiologie de la marche ..............................................................Keir Pearson, (Edmonton, AB)
11:30 Discussion
12:00 Pause déjeuner

INFORMATIONS RÉCENTES SUR LA NEUROIMMUNOLOGIE ET LA NEUROIMAGERIE DE LA Sclérose en plaques
13:15 Autoimmunité dans la sclérose en plaques: une épée à double tranchant.................................Fabrizio Giuliani, (Edmonton, AB)
14:00 Biomarqueurs IRM de pathologie dans la Sclérose en plaques .................................................Ross Mitchell, (Calgary, AB)
14:45 Discussion

ÉPILEPSIE: CONNAISSANCES EN PHYSIOPATHOLOGIE
15:00 Étude de l’anatomie fonctionnelle du système limbique par l’épilepsie du lobe temporal et l’IRM .................................................................Don Gross, (Edmonton, AB)
15:45 Mécanismes de l’Épilepsie ........................................................................................................William Colmers, (Edmonton, AB)
16:30 Discussion et évaluation
SLA: stratégies pour qualité de vie/qualité des soins

Salon 3 - 08:30-17:00

Présidents: David Cameron, Cathy Martin

Objectifs du cours: à l’issue de ce cours les participants sauront:
1. Décrire les spécificités cliniques et physiopathologiques actuelles de la SLA.
2. Reconnaître et appliquer les stratégies pouvant améliorer la fonction et la qualité de vie des personnes ayant une SLA.

Public visé: journée entière de séances interactives avec patients, soignants, personnel paramédical, neurologues, physiatres, organismes d’aide communautaire d’aide et de soutien: tour d’horizon complet des sujets d’actualité dans le domaine de la SLA, y compris diagnostic et recherche, prise en charge et sensibilisation.

08:30 Inscription
09:00 Accueil............................................................................................David Cameron, (Toronto, ON); Cathy Martin, (Edmonton, AB)

SÉANCE I PRÉSENTATION PLÉNIÈRE - PRÉSIDENTS: COLEEN O’CONNELL, SANJAY KALRA
09:10 Mise à jour – Progrès en soins cliniques.....................................................................................Michael Strong, (London, ON)
09:35 Mise à jour – Progrès en sciences fondamentales ..................................................................Denise Figlewicz, (Toronto, ON)
10:00 Séance questions et réponses
10:20 Pause

SÉANCE II PRÉSENTATION EN TABLE RONDE - PRÉSIDENTE: TESSA GORDON
10:40 Point de vue du patient....................................................................................................................................................TBC
11:00 Société SLA de l’Alberta...................................................................................................................................................TBC
11:20 Facteurs de risques environnementaux ............................................................................................Chris White, (Calgary, AB)
11:40 Gérer l’excès de salive: médicaments, botox, irradiation..................................................................................Stuart Cleary, (Edmonton, AB)
12:00 Séance questions et réponses
12:15 Pause déjeuner

SÉANCE III ATELIERS
13:30 Patients, soignants et professionnels des soins de santé - Animateur de discussion: Mary Hatcher
(1) Directives avancées.................................................................................................................................Melinda Hatfield, SW and Jane Rivest, (Calgary, AB)
(2) Quelle est l’utilité des visites à domicile et de télésanté? ...............................................................Pat Carey, (Edmonton, AB)
(3) Sexualité .......................................................................................................................................................Colleen O’Connell, (Fredericton, NB)
13:30 Médecins et chercheurs - Animateur de discussion: Tim Doherty
(1) Rôle de l’EMG, de l’estimation de nombre d’unités motrices, et de la stimulation transcrânienne dans le diagnostic, le suivi et les essais thérapeutiques .................................................................Ming Chan, (Edmonton, AB)
(2) Prise en charge des symptômes................................................................................................................Sanjay Kalra, (Edmonton, AB)
15:00 Pause

SÉANCE IV - PRÉSIDENTS: DAVID CAMERON, MARY HATCHER
15:15 Parler d’espoir avec les patients SLA et leurs familles.................................................................Wendy Johnston, (Edmonton, AB)
15:55 Mots de conclusion et remplissage des feuilles d’évaluation ..........David Cameron, (Toronto, ON); Mary Hatcher, (Halifax, NS)
17:00 Discussion et évaluation
Jour de neuropédiatrie - Controverses et progrès en neurologie néonatale

Présidents: Jerome Yager, Steve Miller

Objectifs du cours: à l’issue de ce symposium les participants pourront:
1. Indiquer les causes les plus fréquentes de lésion neurologique chez le nouveau-né
2. Décrire les conséquences neurologiques de la maladie cardiaque congénitale et être au courant des nouvelles techniques de détection
3. Comprendre les causes et les conséquences des naissances prématurées
4. Exposer les méthodes nouvelles d’intervention thérapeutique chez le nouveau-né qui a une lésion du cerveau.

Public visé: neuropédiatres, pédiatres, néonatologistes, résidents, infirmier(ère)s.

08:30 Introduction
08:40 Ischémie cérébrale néonatale: neuroimagerie comme base pour un traitement rationnel par les cellules souches ..........................................................Stephen Ashwal, (Loma Linda, CA, USA)
09:40 Convulsions néonatales – Est-ce qu’elles abîment le cerveau? ..................................................Lionel Carmant, (Montreal, QC)
10:20 Pause
10:50 Neuroimagerie de pointe et le cerveau du nouveau-né..........................................................Steve Miller, (Vancouver, BC)
11:30 Nouveau regard sur le sort des nourrissons qui ont une maladie cardiaque congénitale....Annette Majnemer, (Montreal, QC)
12:10 Déjeuner
13:30 Est-ce que l’inflammation a de l’importance? .................................................................Guillaume Sebire, (Sherbrooke, QC)
14:10 Quel sort attend le bébé grand prématuré. Quoi de neuf et où allons-nous? .................Charlene Robertson, (Edmonton, AB)
14:50 Interventions thérapeutiques chez le nouveau-né: avons-nous quelque chose à offrir?............Jerome Yager, (Edmonton, AB)
15:40 Pause
16:00 Etude de cas cliniques
16:30 Discussion et évaluation
Séance épilepsie et vidéo

Président: Richard McLachlan

Objectifs du cours: à l’issue de ce symposium, les participants pourront:
1. Comprendre comment utiliser au mieux les vidéos pour faire le diagnostic d’évènements paroxystiques
2. Étudier les caractéristiques électrocliniques des convulsions neuro-métaboliques
3. Revoir l’utilisation des vidéos avec les enfants

Public visé: résidents, fellows et étudiants, neurologues pour adultes et pour enfants, infirmier(ère)s de neurologie et technologistes d’EEG.

18:00 Caractéristiques électrocliniques des causes neuro-métaboliques de l’épilepsie ......................Mary Connolly, (Vancouver, BC)
18:15 Discussion
18:25 Épilepsie au pays de cocagne .............................................................................................................Sam Wiebe, (Calgary, AB)
18:45 Discussion
18:55 Épilepsie chez l’enfant ......................................................................................................................Sharon Whiting, (Ottawa, ON)
19:15 Discussion
19:25 Quelque chose d’intéressant pour chacun .........................................................................................Richard McLachlan, (London, ON)
19:55 Discussion et évaluation

Prise en charge des mouvements anormaux: des médicaments à l’intervention chirurgicale

Cours généreusement financé par une subvention sans condition à but éducatif de Prestwick Pharma.

Président: Richard Camicioli

Objectifs du cours: à l’issue de ce symposium, les participants pourront:
1. Comprendre quelles approches scientifiquement fondées sont utilisables pour traiter la maladie de Parkinson
2. Reconnaître qui peut être candidat à une évaluation chirurgicale du parkinsonisme et des mouvements anormaux hyperkinétiques en ayant pleinement conscience des résultats et des risques
3. Evaluer le traitement scientifiquement fondé pour la chorée, la dyskinésie et la dystonie

Public visé: TBC

18:00 Prise en charge médicale du parkinsonisme .....................................................................................Oksana Suchowersky, (Calgary, AB)
18:25 Prise en charge chirurgicale du parkinsonisme ................................................................................Christopher Honey, (Vancouver, BC)
18:55 Prise en charge médicale de la chorée et de la dystonie ..................................................................Mandar Jog, (London, ON)
19:25 Chirurgie des mouvements anormaux hyperkinétiques ..................................................................Andres Lozano, (Toronto, ON)
19:55 Discussion et évaluation

GROUPES DE PRESSION SPECIALISES

18:00 SLA .........................................................................................................................................................Jasper Room Fairmont Angela Genge
18:00 NEUROMUSCULAIRE .........................................................................................................................Salon 3 Mike Nicolle
18:00 ENSEIGNEMENT AUX RESIDENTS DE NEUROCHIRURGIE .........................................................Drawing Room Fairmont Brian Toyota
18:00 ENSEIGNEMENT DE NEUROLOGIE AUX ETUDIANTS .................................................................Salon 13 & 14 Kevin Busche
Séance plénière d’ouverture: progrès scientifiques et techniques dans le domaine des neurosciences cliniques

Salle 12 - 08:30-10:30

Présidents: Mark Hamilton, Andrew Kirk

Objectifs du cours: À l’issue de ce symposium les participants pourront:

1. Discuter les techniques contemporaines d’imagerie dans les troubles neurologiques
2. Exposer clairement les possibilités de traitement neurochirurgical dans les troubles psychiatriques
3. Décrire l’utilisation de techniques avancées de neuro-imagerie dans le cas d’une lésion traumatique du cerveau chez un enfant

08:30 Accueil et Introduction
08:45 Techniques contemporaines d’imagerie dans les troubles neurologiques ........................................Walter Kucharczyk, (Toronto, ON)*
09:20 Approches contemporaines neurochirurgicales dans le traitement des troubles psychiatriques ............................................Andres Lozano, (Toronto, ON)*
09:55 Conférence Tibbles – le cerveau qui paraît normal n’est pas normal – Utilisation des techniques de pointe de neuroimagerie ........................................Steve Ashwal, (Loma Linda, CA, USA)*

* Parraine par le College royal des médecins et chirurgiens du Canada.

Présentation plénière choisie par le Président

Salle 12 - 10:45-12:15

Douleur neuropathique - Physiopathologie, prévention et prise en charge

Drawing Room Fairmont - 14:00-17:30

Cours généreusement financé par une subvention sans condition à but éducatif de Pfizer Inc.

Président: Dwight Moulin

Objectifs du cours: à l’issue de ce cours les participants pourront:

1. Comprendre la physiopathologie de la douleur neuropathique pour la prendre comme base de traitement
2. Avoir une approche basée sur des faits prouvés pour prendre en charge la douleur neuropathique
3. Reconnaître la valeur de substances nouvelles dans la prévention et la prise en charge de la douleur neuropathique

Public visé: médecins de famille, neurologues, neurochirurgiens et infirmier(e)s praticien(ne)s cliniques.

14:00 Prévalence et physiopathologie de la douleur neuropathique ........................................Dwight Moulin, (London, ON)
14:30 Discussion
14:45 Névralgie post-herpétique - bilan et prise en charge .........................................................Peter Watson, (Toronto, ON)
15:15 Discussion
15:30 Pause alimentaire
15:45 Consignes basées sur des faits prouvés pour prendre en charge la douleur neuropathique ......Dwight Moulin, (London, ON)
16:30 Substances nouvelles pour prendre en charge la douleur neuropathique ........................................John Clark, (Calgary, AB)
17:00 Discussion et évaluation
**Cours sur la colonne vertébrale – Triage et prise en charge du patient qui a une myélopathie spondylotique cervicale**  
*Wedgewood Fairmont* - 14:00-17:30

**Président:** Eric Massicotte

**Objectifs du cours:** à l’issue de ce symposium les participants pourront:
1. Saisir et comprendre la difficulté d’évaluer les patients qui ont une myélopathie. Indiquer les indices qui peuvent aider à établir un diagnostic correct.
2. Discuter les options de prise en charge de ces malades
3. Faire le point sur les approches chirurgicales spécifiques de la spondylite
4. Expliquer clairement le rôle des techniques peu invasives et reconstructives chez ces patients

**Public visé:** les neurologues et neurochirurgiens en formation ou à la pratique bien établie ainsi que les prestataires de soins de santé peuvent tirer bénéfice de cette séance.

<table>
<thead>
<tr>
<th>14:00</th>
<th>Difficultés de diagnostic: quels sont les indices cliniques ?</th>
<th>Robert Chen, (Toronto, ON)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Histoire naturelle de la spondylose et de la myélopathie</td>
<td>Richard Fox, (Edmonton, AB)</td>
</tr>
<tr>
<td>14:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Approches antérieures dans la spondylose cervicale</td>
<td>Steve Casha, (Calgary, AB)</td>
</tr>
<tr>
<td>15:15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Approches postérieures dans la spondylose cervicale</td>
<td>Ramesh Sahjpal, (Vancouver, BC)</td>
</tr>
<tr>
<td>15:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Pause</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Rôle des techniques peu invasives</td>
<td>Sean Christie, (Halifax, NS)</td>
</tr>
<tr>
<td>16:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td>Stratégies de reconstruction complexe</td>
<td>Eric Massicotte, (Toronto, ON)</td>
</tr>
<tr>
<td>17:00</td>
<td>Issue fonctionnelle de la myélopathie spondylosique cervicale</td>
<td>Sukhuinder Kalsi-Ryan, (Toronto, ON)</td>
</tr>
<tr>
<td>17:10</td>
<td>Discussion et évaluation</td>
<td></td>
</tr>
</tbody>
</table>
Cours d’électromyographie clinique (voir ci-dessous pour l’attribution des salles) - 14:00-17:30

Les ateliers 1, 2, et 4 se tiendront au Shaw Centre. L’atelier 3 se tiendra à l’Université de l’Alberta [le transport n’est pas assuré]. Seuls les ateliers 1, 2, et 4 auront 2 séances.

Présidents: Ming Chan, Joseph Chu

Objectifs du cours: à l’issue de ce symposium les participants pourront:
1. Comprendre l’approche électrodiagnostique pour faire le bilan de la SLA et des syndromes lui ressemblant
2. Faire le point sur l’EMG d’une seule fibre
3. Décrire les tests électrodiagnostiques et identifier les nerfs rarement étudiés du membre supérieur
4. Discuter les perles et les pièges de l’EMG en particulier pour les muscles inhabituels

Public visé: neurologues, EMGrapheurs, fellows et résidents de neurologie, physiologistes et techniciens d’EMG.

14:00 & 16:00 Atelier 1: approche électrodiagnostique pour le bilan de la SLA et des syndromes lui ressemblant ......................Salon 15
..................................................................................................................................................Chris White, (Calgary, AB)
14:00 & 16:00 Atelier 2: EMG d’une seule fibre ...........................................................................................Salon 16 Michael Nicolle, (London, ON)
14:00 Atelier 3: identification anatomique et test électrodiagnostique de nerfs rarement étudiés du membre supérieur ..........Université de l’Alberta Lalith Satkunam, (Edmonton, AB); Ian Grant, (Halifax, NS); Michael Morhart, (Edmonton, AB)
14:00 & 16:00 Atelier 4: EMG de muscles inhabituels et quel intérêt ils ont dans l’électrodiagnostic en neurologie ....................Salon 19 Jasper Daube, (Rochester, MN, USA)

Cours sur l’accident vasculaire cérébral Salon 2 - 14:00-17:30

Cours généreusement financé par une subvention sans condition à but éducatif de Sanofi-aventis/Bristol-Myers Squibb.

Présidents: Khurshid Khan, Ashfaq Shuaib

Objectifs du cours: à l’issue de ce cours les participants pourront:
1. Analyser les mécanismes physiopathologiques contribuant à l’athérosclérose et aux divers types d’attaques cérébrales.
2. Étudier en détail les diverses technologies nouvelles d’imagerie aidant à établir un diagnostic en présence d’une attaque cérébrale
3. Trouver les meilleures options thérapeutiques pour des sous-types spécifiques d’accident vasculaire cérébral
4. Juger de manière critique les nouvelles thérapies d’apparition récente dans le domaine de la maladie vasculaire cérébrale.

Public visé: TBC

14:00 Prise en charge de l’accident vasculaire cérébral aigu .................................................................Philip Teal, (Vancouver, BC)
14:25 Discussion
14:35 Prévention de l’AVC .......................................................................................................................Ashfaq Shuaib, (Edmonton, AB)
15:00 Discussion
15:10 Neuroimagerie (CT/IRM) dans l’AVC aigu ......................................................................................Ken Butcher, (Edmonton, AB)
15:35 Discussion
15:40 Pause
15:50 Hémorragie intracérébrale ..........................................................................................Matthew Hogan, (Ottawa, ON)
16:15 Discussion
16:25 Approche neurochirurgicale des conditions cérébrovasculaires “asymptômatiques” (y compris maladie de la carotide, anévrismes, et malformations vasculaires) .................................................................Max Findley, (Edmonton, AB)
16:50 Discussion
17:00 Procédures endovasculaires .................................................................................................Michael Chow, (Edmonton, AB)
17:25 Discussion et évaluation
Cours sur l’épilepsie: épilepsie réfractaire

Président: Richard Wennberg

Objectifs du cours: à l’issue de ce symposium, les participants pourront:
1. Reconnaître les patients présentant une épilepsie réfractaire
2. Evaluer le fardeau qu’est l’épilepsie réfractaire au Canada
3. Comprendre quand et pourquoi envoyer les patients à des centres spécialisés pour l’épilepsie


14:00 Introduction
14:10 Épilepsie réfractaire de l’adulte: vue d’ensemble et explorations cliniques ...........................................Don Gross, (Edmonton, AB)
14:30 Discussion
14:35 Épilepsie réfractaire de l’adulte: épidémiologie et fardeau économique: ....................................................Sam Wiebe, (Calgary, AB)
14:55 Discussion
15:00 Épilepsie réfractaire de l’adulte: chirurgie ..........................................................................................Andrew Parrent, (London, ON)
15:20 Discussion
15:25 Pause
15:40 Neuroimagerie dans l’épilepsie réfractaire de l’adulte ........................................................................Andrea Bernasconi, (Montreal, QC)
16:00 Discussion
16:05 Construction d’un centre pluridisciplinaire spécialisé pour l’épilepsie ........................................................Taufik Valiente, (Toronto, ON)
16:25 Discussion
16:30 Épilepsie réfractaire de l’enfant: vue d’ensemble et explorations cliniques ...........................................Mary Connolly, (Vancouver, BC)
16:50 Discussion
16:55 Épilepsie réfractaire de l’enfant: chirurgie ..........................................................................................James Rutka, (Toronto, ON)
17:15 Discussion et évaluation

Cours sur les soins intensifs neurologiques

Présidents: Draga Jichici, Jeanne Teitelbaum

Objectifs du cours: à l’issue de ce symposium les participants sauront:
1. Appliquer un traitement hypothermique à certains groupes de patients
2. Traiter de manière efficace l’état de mal épileptique
3. Comprendre les imitations de mort cérébrale
4. Évaluer et diagnostiquer la faiblesse neuromusculaire dans le service de soins intensifs
5. Analyser les techniques nouvelles pour diagnostiquer et prendre en charge le traumatisme crânien
6. Faire le prognostic du résultat après un arrêt cardiaque

Public visé: neurologues en pratique clinique, neurochirurgiens, médecins intensivistes, résidents et infirmier(ère)s.

14:00 Prise en charge de l’état de mal épileptique ..................................................................................Martin Savard, (London, ON)
14:30 Hypothermie en soins intensifs neurologiques: quand l’utiliser ..................................................Draga Jichici, (Hamilton, ON)
15:15 Approches nouvelles de la faiblesse musculaire généralisée dans les unités de soins intensifs.Charles Bolton, (Kingston, ON)
15:45 Mort cérébrale: ou non? ........................................................................................................Jeanne Teitelbaum, (Montreal, QC)
16:15 Quoi de neuf dans la prise en charge du traumatisme crânien: la microdialyse ........................................David Zygun, (Calgary, AB)
16:45 Discussion et évaluation
Séance plénière: SNC, ACNP, et SCNC neurologie  

**Salle 12 - 08:30-10:00**

**Président:** Richard Desbiens

**Objectifs du cours:** à l’issue de ce symposium les participants sauront:

1. Discuter les faits nouveaux dans la prise en charge des myopathies inflammatoires
2. Comprendre les causes de la “paralysie cérébrale infantile”, le déroulement de la vie des personnes nées avec cette maladie, et les grandes lignes pour la prise en charge de ces patients.

08:30  Accueil et introduction
08:35  Conférence Gloor - Myopathies inflammatoires - Faits nouveaux ...........................................Tony Amato, (Boston, MA, USA)
09:20  Conférence Richardson - Une cible en mouvement: les difficultés contemporaines dans le domaine de la paralysie générale infantile tout au long de l’existence ..........................................................Michael Shevell, (Montreal, QC)

Séance plénière: SCNCH neurochirurgie  

**Salle 2 - 08:30-10:00**

**Président:** Derek Fewer

**Objectifs du cours:** à l’issue de ce symposium les participants pourront:

1. Comprendre les principes de la neurochirurgie endoscopique
2. Analyser les résultats et les complications de la neurochirurgie endoscopique
3. Discuter le traitement chirurgical et endovasculaire des fistules artério-veineuses durales.

08:30  Accueil et introduction
08:35  Conférence Penfield - Principes de neurochirurgie endoscopique: résultats et complications sur dix ans et 700 patients . ..........................................................Amin Kassam, (Pittsburgh, PA, USA)
09:20  Prise en charge chirurgicale et endovasculaire des fistules artério-veineuses intracrâniennes et rachidiennes .......... Charles Haw, (Vancouver BC)

**Communications orales libres (6 simultanément)**  

**Salon 2,3,4,5,6 & 12,13,14 - 10:15-12:30**

**Déjeuner / communications par affiches électroniques et tour de l’exposition**  

**Salon 8,9,10,11 - 12:30-14:00**

**Communications orales libres (7 simultanément)**  

**Salon 2,3,4,5,6 & 12,13,14,15,16 - 14:00-16:30**

**Communications par affiches électroniques et tour de l’exposition**  

**Salon 8,9,10,11 - 16:30-18:00**
Conférence par l’invité de marque
Séance plénière généreusement financée par une subvention sans condition à but éducatif du Journal canadien des Sciences neurologiques.

Objectifs du cours: à l’issue de ce symposium les participants sauront:
1. Analyser l’histoire de l’évolution de la neurochirurgie et de la neurologie.
2. Discuter le fardeau que constituent la maladie, les troubles et les lésions neurologiques au Canada

08:30 Accueil et introduction
08:40 De Osler à Cushing – essor de la médecine, essor de la neurochirurgie ......................... Michael Bliss, (Toronto, ON)

Compte-rendu de la CCSCNP

09:30 Le fardeau que constituent la maladie, les troubles et les lésions neurologiques au Canada .......................................................... Charles Tator, (Toronto, ON); Garth Bray, (Montreal, QC)

Remise du prix JCSN 2007 Eminent relecteur de manuscrits

Communications par affiches électroniques et tour de l’exposition

Discussion de cas cliniques
Présidents: Richard Camicioli, Michael Hill

Objectifs du cours: à l’issue de ce symposium les participants sauront:
Utiliser le format de la discussion de cas cliniques pour une discussion multidisciplinaire et interactive de malades.

Cas neurologique: .................................................................................................. Taim Muayqil, (Zaeem Sidiqui, Richard Camicioli)
Dépression et déficit cognitif léger
Cas neurochirurgical: ............................................................................................ Fred Lam, (Matt Wheatley, Wendy Johnston, Ted Roberts)
La maladie du neurone moteur et le neurochirurgien
Cas neuro-pédiatrique: ............................................................................................ Vijay Ramaswamy, (Lawrence Richer, Hanna Kolski)
Kystes bilatéraux et hémorragie sous-durale spontanée

Déjeuner / Communications par affiches électroniques et tour de l’exposition

VENDREDI 22 JUIN 2007 PROGRAMME SCIENTIFIQUE
Cours sur les céphalées

**Salon 2 - 13:30-17:00**

**Président:** Marek Gawel

**Objectifs du cours:** à l’issue de ce symposium les participants sauront:

1. Evaluer les facteurs entrant en jeu et l’étiologie de la céphalée chronique chez leurs patients
2. Unifier leurs connaissances en physiopathologie et les causes pharmacologiques de la céphalée chronique
3. Établir un plan de traitement pluridisciplinaire
4. Choisir les thérapies pharmacologiques et non pharmacologiques adéquates pour la céphalée chronique

**Public visé:** neurologues généraux

<table>
<thead>
<tr>
<th>Heure</th>
<th>Sujet</th>
<th>Président</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Accueil</td>
<td>Marek Gawel, (Toronto, ON)</td>
</tr>
<tr>
<td>13:45</td>
<td>Progrès récents en physiopathologie, y compris les données récentes TEP</td>
<td>Michael Aubé, (Montreal, QC)</td>
</tr>
<tr>
<td>14:00</td>
<td>Lésions du FOP et de la substance blanche du SNC dans la migraine: concepts actuels</td>
<td>Werner Becker, (Calgary, AB)</td>
</tr>
<tr>
<td>14:15</td>
<td>Céphalée chronique du type céphalée de tension</td>
<td>Michael Aubé, (Montreal, QC)</td>
</tr>
<tr>
<td>14:45</td>
<td>Migraine transformée</td>
<td>Lara Cooke, (Calgary, AB)</td>
</tr>
<tr>
<td>15:15</td>
<td>Céphalée du type céphalée de tension chez l’enfant</td>
<td>Shashi Seshia, (Saskatoon, SK)</td>
</tr>
<tr>
<td>15:30</td>
<td>Céphalée post-traumatique</td>
<td>Marek Gawel, (Toronto, ON)</td>
</tr>
<tr>
<td>16:00</td>
<td>Céphalée en grappe chronique et céphalées trigéminales autonomes</td>
<td>Suzanne Christie, (Ottawa, ON)</td>
</tr>
<tr>
<td>16:30</td>
<td>Discussion et évaluation</td>
<td></td>
</tr>
</tbody>
</table>

Cours: quoi de neuf en neurochirurgie

**Drawing Room Fairmont - 13:30-17:00**

**Président:** Rick Moulton

**Objectifs du cours:** à l’issue de ce symposium les participants sauront :

1. Analyser les différentes possibilités de prise en charge de patients ayant une hydrocéphalie et les résultats
2. Identifier les nouveaux traitements et les options de prise en charge des malformations artério-veineuses (MAV)
3. Exposer clairement les récentes options de traitement et les résultats s’y rapportant dans le traumatisme grave du cerveau
4. Discuter les traitements nouveaux et les options de prise en charge de patients qui ont un gliome
5. Choisir des stratégies de prise en charge adéquates pour les métastases spinales
6. Comparer les résultats et les options de traitement pour l’épilepsie du lobe temporal

**Public visé:** neurochirurgiens, résidents de neurochirurgie, neurologues

<table>
<thead>
<tr>
<th>Heure</th>
<th>Sujet</th>
<th>Président</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Hydrocéphalie</td>
<td>Ab Kulkarni, (Toronto, ON)</td>
</tr>
<tr>
<td>14:00</td>
<td>MAVs</td>
<td>Ian Fleetwood, (Halifax, NS)</td>
</tr>
<tr>
<td>14:30</td>
<td>Traumatisme grave du cerveau</td>
<td>Rick Moulton, (Ottawa, ON)</td>
</tr>
<tr>
<td>15:00</td>
<td>Gliomes</td>
<td>Ian Parney, (Calgary, AB)</td>
</tr>
<tr>
<td>15:30</td>
<td>Métastases spinales</td>
<td>Daryl Fourney, (Saskatoon, SK)</td>
</tr>
<tr>
<td>16:00</td>
<td>Epilepsie du lobe temporal</td>
<td>Matt Wheatley, (Edmonton, AB)</td>
</tr>
<tr>
<td>16:30</td>
<td>Discussion et évaluation</td>
<td></td>
</tr>
</tbody>
</table>

**Edmonton, Alberta**
Cours sur l’EEG

Salon 4 - 13:30-17:00

Président: Seyed Mirsattari

Objectifs du cours: à l’issue de ce symposium les participants sauront:
1. Reconnaître les caractéristiques EEG normales et anormales habituellement rencontrées chez les patients qui ont une épilepsie
2. Analyser les caractéristiques EEG du nouveau-né et de l’enfant
3. Saisir les bases de la technologie EEG, y compris la technologie numérique

Public visé: neurologues, résidents de neurologie et neuro-pédiatres

13:30 EEG du nouveau-né - normal et anormal .................................................................Eli M. Mizrahi, (Houston, TX, USA)
14:15 Discussion
14:20 EEG de l’enfant .........................................................................................................Warren T. Blume, (London, ON)
15:05 Discussion
15:10 Pause
15:15 EEG de l’adulte - normal et chez les patients qui ont une épilepsie .......................Richard S. McLachlan, (London, ON)
16:00 Discussion
16:05 Bases de la technologie EEG, l’accent étant mis sur les techniques numérales ..........Susan Rahey, (Halifax, NS)
16:50 Discussion et évaluation

Cours sur la démence

Salon 3 - 13:30-17:00

Cours généreusement financé par une subvention sans condition à but éducatif de Pfizer Inc.

Président: Gabriel Léger

Objectifs du cours: à l’issue de ce symposium les participants sauront:
1. Reconnaître les présentations habituelles des démences non-Alzheimer (mixte/vasculaire, à corps de Lewy/maladie de Parkinson, et fronto-temporale), et comment elles diffèrent de la maladie d’Alzheimer typique (MA)
2. Utiliser au chevet du patient des tests cognitifs sensibles qui aident à différencier ces démences de la MA.
3. Diagnostiquer ces démences à partir des critères du consensus diagnostique actuel.
4. Déterminer un plan de traitement adapté à la démence non-Alzheimer, incluant les médicaments à utiliser et ceux à éviter

Public visé: neurologues

13:30 De la démence vasculaire au déficit cognitif vasculaire ..................................................Christian Bocti, (Montreal, QC)
14:15 Discussion
14:45 Démence de la maladie de Parkinson et maladie à corps de Lewy ..................................Céline Chayer, (Montreal, QC)
15:30 Discussion
15:45 Diagnostic et prise en charge des démences fronto-temporales ...................................Gabriel Léger, (Montreal, QC)
16:30 Discussion et évaluation
Cours sur la SEP

**Président:** Kenneth Warren

**Objectifs du cours:** à l’issue de ce symposium les participants sauront:
1. Comprendre l’ampleur et la nature de la SEP dans la société canadienne
2. Discuter les changements qualitatifs et quantitatifs dans le liquide céphalo-rachidien et les caractéristiques neuropathologiques de la SEP
3. Analyser comment les progrès récents en pathologie et en pharmacologie affectent la prise en charge de la SEP

**Public visé:** neurologues généraux et neurologues spécialisés en SEP.

<table>
<thead>
<tr>
<th>13:30</th>
<th><strong>Progrès IRM</strong></th>
<th>Derrick Emery, (Edmonton, AB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>13:50</td>
<td><strong>Changements démographiques et tendances cliniques</strong></td>
<td>Sharon Warren, (Edmonton, AB)</td>
</tr>
<tr>
<td>14:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:10</td>
<td><strong>Qualité de vie</strong></td>
<td>Karen Turpin, (Edmonton, AB)</td>
</tr>
<tr>
<td>14:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td><strong>Variabilité neuropathologique</strong></td>
<td>Lothar Resch, (Edmonton, AB)</td>
</tr>
<tr>
<td>14:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td>Pause</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td><strong>Mort neuronale et neuroprotection</strong></td>
<td>Fabrizio Giuliani, (Edmonton, AB)</td>
</tr>
<tr>
<td>15:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Nouvelles tendances thérapeutiques</strong></td>
<td>Greg Blevins, (Edmonton, AB)</td>
</tr>
<tr>
<td>15:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:50</td>
<td><strong>Neurovirologie</strong></td>
<td>Chris Power, (Edmonton, AB)</td>
</tr>
<tr>
<td>16:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td><strong>Experiences de patients hébergés au long cours</strong></td>
<td>Garry Wheeler, (Edmonton, AB)</td>
</tr>
<tr>
<td>16:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Anticorps dans le LCR</strong></td>
<td>Ingrid Catz, (Edmonton, AB)</td>
</tr>
<tr>
<td>16:45</td>
<td>Discussion et évaluation</td>
<td></td>
</tr>
</tbody>
</table>
Cours: quoi de neuf en neurologie?

**Président:** Ashfaq Shuaib

**Objectifs du cours:** à l'issue de ce symposium les participants pourront:

1. Discuter des options nouvelles de traitement et de prise en charge de la SLA
2. Analyser les progrès faits dans le traitement des infections du SNC
3. Décrire les options de traitement et les nouveaux traitements des tumeurs du SNC
4. Expliquer clairement les progrès faits dans le domaine de la maladie neuromusculaire
5. Décrire les options récentes dans le traitement de l’hémorragie intracrânienne

**Public visé:** neurologues, résidents de neurologie, infirmier(ère)s, fellows et neurochirurgiens.

13:30 Introduction
13:40 *Quoi de neuf dans le neuromusculaire?* ................................................................. Douglas Zochodne, (Calgary, AB)
14:15 Discussion
14:20 *Quoi de neuf dans les infections?* ................................................................................ Chris Power, (Edmonton, AB)
14:55 Discussion
15:00 *Quoi de neuf dans l’hémorragie intracrânienne?* .................................................... Ashfaq Shuaib, (Edmonton, AB)
15:35 Discussion
15:40 *Quoi de neuf en SLA?* ................................................................................................. Mike Strong, (London, ON)
16:15 Discussion
16:20 *Quoi de neuf dans les tumeurs du SNC?* ................................................................. Ian Parney (Calgary, AB)
16:55 Discussion et évaluation
Cours sur le neuromusculaire

Président: Mike Nicolle

Objectifs du cours: à l’issue de ce symposium les participants sauront:
1. Différencier et prendre en charge les neuropathies de compression fréquentes et rares
2. Diagnostiquer les troubles affectant les plexus brachial et lombo-sacré
3. Expliquer la relation entre la physiologie de base de la fonction nerveuse et la pathologie des nerfs périphériques dans le diabète.
4. Expliquer clairement les manifestations cliniques des neuropathies diabétiques.
5. Combiner leurs connaissances sur les mécanismes génétiques de la dystrophie myotonique congénitale avec les manifestations cliniques et les tests diagnostiques existant.

Public visé: travailleurs dans le domaine des soins de santé, résidents et fellows de neurologie et de physiatrie, neurologues et physiatres pratiquant dans une université ou dans la communauté, tous s’intéressant à la neurologie neuromusculaire et à la physiatrie.

13:30 Neuropathies périphériques focales: gros plan sur les difficultés spécifiques de diagnostic et de prise en charge .................
.................................................................................................................................................John Stewart, (Vancouver, BC)
14:00 Discussion
14:15 Plexopathies brachiale et lombo-sacrée: dilemnes cliniques et variantes atypiques ........Kristine Chapman, (Vancouver, BC)
14:45 Discussion
15:00 Pause
15:30 Dystrophie myotonique congénitale: analyse et mise à jour par l’étude canadienne de surveillance et de cohorte ...........
.................................................................................................................................................Craig Campbell, (London, ON)
16:00 Discussion
16:15 Neuropathie diabétique: nouvelles directions .................................................................Douglas Zochodne, (Calgary, AB)
16:45 Discussion et évaluation
BIOVISIONARY

As a leading provider of life-saving protein therapeutics, Talecris is dedicated to achieving the next level of excellence. With a strong commitment to innovation, we continue to make advances to enrich patients' lives. Visit us at www.talecris.com.
The Canadian Neurological Sciences Federation (CNSF) and
The Canadian Journal of Neurological Sciences (CJNS)

2006 – 2007 Board of Directors and Committee Chairs

Mark Hamilton
- CNSF President
- CJNS President
- CNSS Past President

Garth Bray
- CNSF Vice-President
- CJNS Vice-President
- CNS

Brian Wheelock
- CNSF Vice-President
- CJNS Vice-President
- CNSS

Joseph Dooley
- CNSF Board member
- CJNS Board member
- CACN President

Douglas Zochodne
- CJNS Editor-in-Chief

Jerome Yager
- CNSF Board Member
- CJNS Board Member
- CACN Vice-President

Derek Fewer
- CNSF Board Member
- CJNS Board Member
- CNSS President

J. Max Findlay
- CNSF Board Member
- CJNS Board Member
- CNSS Vice-President

Andrew Kirk
- CNSF Board Member
- CJNS Board Member
- CNS President

Sam Wiebe
- Publications Committee Chair

Richard Desbiens
- CNSF Board Member
- CJNS Board Member
- CNS Vice-President

George Elleker
- CNSF Board Member
- CJNS Board Member
- CSCN President

Manouchehr Javidan
- CNSF Board Member
- CJNS Board Member
- CSCN Vice-President

Morris Freedman
- CNSF Board Member
- CJNS Board Member
- CNS Past President

John Stewart
- CNSF Scientific Program Committee Chair

Carmela Tartaglia
- CNSF Residents' Rep
- CJNS Residents' Rep
- CNS

Dan Morin
- CNSF Board Member
- CJNS Board Member
- CNSF CEO

Sue Brien
- CNSF Professional Development Committee Chair
- CNSS Accreditor

Charles Tator
- CBANHC Chair
- CNSS

Legend:
CNSF - Canadian Neurological Sciences Federation; CJNS - Canadian Journal of Neurological Sciences; CNS - Canadian Neurological Society; CNSS - Canadian Neurosurgical Society; CSCN - Canadian Society of Clinical Neurophysiologists; CACN - Canadian Association of Child Neurology; CBANHC - Canadian Brain and Nerve Health Coalition
sanofi-aventis and Bristol-Myers Squibb and are proud to be Gold sponsors of the 2007 Canadian Neurological Sciences Federation Congress.

Sanofi-aventis Canada Inc. is an affiliate of the global sanofi-aventis organization, the world’s third-largest pharmaceutical company. In Canada, the company provides medications in the areas of cardiology, thrombosis, oncology, metabolic disorders and internal medicine. It is headquartered in Laval, Quebec, and employs 1,140 people.

Bristol-Myers Squibb Canada is an indirect wholly owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Company of Canada is a leading provider of medicines to fight cancer; cardiovascular and metabolic disorders; infectious diseases, including HIV/AIDS; nervous system diseases; and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE:BMY). Bristol-Myers Squibb Canada’s operations are headquartered in Montreal, Quebec.
The Canadian Neurological Sciences Federation is pleased to recognize our Sponsors* for 2007. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries. Along with support of the Canadian Journal of Neurological Sciences and other initiatives the CNSF maintains throughout the year, these organizations graciously provide unrestricted educational grants to the Annual Congress, this year in Edmonton, Alberta; June 19th – 22, 2007.

La Fédération des sciences neurologiques du Canada est heureuse de reconnaître nos commanditaires* pour l’année 2007. Ces organisations forment un partenariat avec la FSNC pour déterminer les causes des maladies et des lésions du système nerveux, pour leur trouver un traitement, et pour s’occuper des patients qui ont ces maladies et lésions. Parallèlement à l’aide financière qu’elles apportent au Journal canadien des sciences neurologiques et à d’autres initiatives que la FSNC aide tout au long de l’année, ces organisations octroient gracieusement des subventions sans condition à but éducatif au congrès annuel qui a lieu cette année à Edmonton, Alberta, du 19 au 22 juin 2007.

Platinum

Gold

Silver
Hoffman La-Roche

Bronze
Talecris Biotherapeutics
Prestwick Pharmaceuticals
CJNS
Canadian Neurological Society Foundation
Novartis

Supporters
Bayer Inc.
Merck Frosst
Codman Neuro & Depuy Spine
XLTek
Roxon Medi-Tech
Medtronic of Canada
Genmark Canada
Teva Neuroscience
Valeant Canada Ltd.
Canada Microsurgical
Carl Zeiss Canada
Neurochem
Galen Medical Ltd.